

# CITATION REPORT

List of articles citing

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

DOI: 10.1182/blood-2007-06-093906  
Blood, 2008, 111, 5446-56.

**Source:** <https://exaly.com/paper-pdf/44130530/citation-report.pdf>

**Version:** 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2336	Mature B-cell leukemias. 171-190		
2335	Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. <b>2008</b> , 57, 1705-10		14
2334	Chronisch lymphatische Leukämie (CLL). <b>2008</b> , 3, 81-91		
2333	FISH in der Diagnostik hämatologischer Neoplasien. <b>2008</b> , 20, 367-373		
2332	Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders. <b>2008</b> , 1, 211-222		1
2331	Chronische lymphatische Leukämie. <b>2008</b> , 3, 26-37		
2330	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <b>2008</b> , 88, 374-380		11
2329	Current Awareness in Hematological Oncology. <b>2008</b> , 26, 253-260		
2328	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. <b>2008</b> , 26, 247-51		34
2327	How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. <b>2008</b> , 22, 2257-8		19
2326	Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. <b>2008</b> , 143, 690-7		41
2325	Chronic lymphocytic leukemia: a hazardous condition before kidney transplantation. <b>2008</b> , 8, 2471-5		7
2324	Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. <b>2008</b> , 359, 575-83		447
2323	CD38 at the junction between prognostic marker and therapeutic target. <b>2008</b> , 14, 210-8		59
2322	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 975-80	2.2	568
2321	Indolent lymphomas other than follicular and marginal zone lymphomas. <b>2008</b> , 22, 903-40, viii		5
2320	Current Treatment for Chronic Lymphocytic Leukemia. <b>2008</b> , 2, 230-236		0

2319	Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. <b>2008</b> , 10, 442-51		64
2318	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. <b>2008</b> , 49, 2108-15		43
2317	Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia. <b>2008</b> , 100, E1		
2316	Inherited predisposition to chronic lymphocytic leukemia. <b>2008</b> , 1, 51-61		17
2315	Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. <b>2008</b> , 26, 5094-100	139	
2314	Peripheral blood lymphocytosis--what is the threshold for further investigation?. <b>2008</b> , 49, 1659-61		2
2313	Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. <b>2008</b> , 359, 2065-6; author reply 2066		25
2312	Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects?. <b>2008</b> , 49, 1651-2		
2311	Molecular profiling in CLL. <b>2008</b> , 444-9		21
2310	Epidemiology, pathology and treatment of non-follicular indolent lymphomas. <b>2008</b> , 49 Suppl 1, 35-42		15
2309	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 1923-30	2.2	254
2308	SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. <i>Blood</i> , <b>2008</b> , 112, 394-7	2.2	37
2307	Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. <i>Blood</i> , <b>2009</b> , 114, 4761-70	2.2	81
2306	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. <b>2009</b> , 27, 3959-63		109
2305	Allotransplantation for chronic lymphocytic leukemia. <b>2009</b> , 602-9		26
2304	Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. <b>2009</b> , 50, 1589-96		24
2303	Monoclonal B-cell lymphocytosis. <b>2009</b> , 430-9		36
2302	Bendamustine therapy in chronic lymphocytic leukemia. <b>2009</b> , 10, 1687-98		1

2301	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. <b>2009</b> , 15, 995-1004	245
2300	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. <b>2009</b> , 15, 4415-22	155
2299	Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. <b>2009</b> , 27, 3808-14	125
2298	Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up. <b>2009</b> , 20 Suppl 4, 102-4	11
2297	Comparative analysis of normal versus CLL B-lymphocytes reveals patient-specific variability in signaling mechanisms controlling LFA-1 activation by chemokines. <b>2009</b> , 69, 9281-90	33
2296	Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. <b>2009</b> , 15, 1123-5	23
2295	A case of chronic lymphocytic leukemia with deletion 17p and bilateral retinal leukemic infiltrates. <b>2009</b> , 82, 79-80	4
2294	Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. <b>2009</b> , 82, 133-42	10
2293	Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. <b>2009</b> , 83, 156-8	5
2292	Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. <b>2009</b> , 83, 208-14	8
2291	FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia. <b>2009</b> , 83, 541-9	12
2290	Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <b>2009</b> , 31 Pt 2, 2290-311	31
2289	Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. <b>2009</b> , 195, 97-104	25
2288	High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. <b>2009</b> , 131, 472-80	27
2287	Richter syndrome: molecular insights and clinical perspectives. <b>2009</b> , 27, 1-10	95
2286	How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia. <b>2009</b> , 27, 186-9	3
2285	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. <b>2009</b> , 115, 363-72	64
2284	Chronic lymphocytic leukemia: treatment options for patients with refractory disease. <b>2009</b> , 115, 3830-41	10

2283	Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. <b>2009</b> , 76, 385-93	27
2282	DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. <b>2009</b> , 48, 760-7	22
2281	The use of tetradecanoylphorbol acetate-stimulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia. <b>2010</b> , 49, 327-32	7
2280	Chronic lymphocytic leukemia: new concepts and emerging therapies. <b>2009</b> , 10, 16-32	7
2279	Prognostic factors in low-grade non-Hodgkin lymphomas. <b>2009</b> , 4, 202-10	11
2278	Leukemias. <b>2009</b> , 2, 53-58	
2277	Chronic lymphocytic leukaemia: an update. <b>2009</b> , 2, 142-145	1
2276	Recent advances in bone marrow biopsy pathology. <b>2009</b> , 2, 151-6	
2275	[Role of multicenter study groups for clinical research in hematology and oncology]. <b>2009</b> , 52, 417-24	2
2274	Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. <b>2009</b> , 144, 78-85	26
2273	Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. <b>2009</b> , 144, 507-16	101
2272	Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. <b>2009</b> , 145, 801-5	38
2271	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. <b>2009</b> , 146, 44-53	46
2270	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <b>2009</b> , 146, 64-75	120
2269	Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. <b>2009</b> , 39, 497-506	26
2268	Abstracts of the XXII International Symposium on Technological Innovations in Laboratory Hematology. May, 11-14, 2009. Las Vegas, Nevada, USA. <b>2009</b> , 31 Suppl 1, 1-111	
2267	The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. <b>2009</b> , 23, 117-24	167
2266	Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. <b>2009</b> , 23, 919-24	64

2265	A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2009</b> , 23, 912-8	24
2264	Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. <b>2009</b> , 23, 1011-7	23
2263	Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. <b>2009</b> , 23, 2007-17	77
2262	Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. <b>2009</b> , 23, 2018-26	26
2261	Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. <b>2009</b> , 23, 1771-8	40
2260	Chronic lymphocytic leukaemia: current first-line therapy. <b>2009</b> , 39, 44-8	4
2259	Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis. <b>2009</b> , 33, 1619-22	4
2258	Just exactly how common is CLL?. <b>2009</b> , 33, 1452-3	10
2257	Glutamate dehydrogenase activity in lymphocytes of B-cell chronic lymphocytic leukaemia patients. <b>2009</b> , 42, 1677-84	6
2256	Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. <b>2009</b> , 23, 25-47	92
2255	Emerging therapies for patients with advanced chronic lymphocytic leukaemia. <b>2009</b> , 23, 217-24	14
2254	Treatment of elderly patients with chronic lymphocytic leukemia. <b>2009</b> , 50, 171-8	87
2253	Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. <b>2009</b> , 27, 498-503	154
2252	Gene expression profiling in chronic lymphocytic leukaemia. <b>2009</b> , 22, 211-22	18
2251	Stem cell transplantation in chronic lymphocytic leukemia. <b>2009</b> , 15, 53-8	37
2250	Facteurs pronostiques utiles dans l'évaluation personnalisée d'un patient avec une leucémie lymphoïde chronique (LLC). <b>2009</b> , 24, 1-8	
2249	[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment]. <b>2009</b> , 38, 140-2	
2248	Current and emerging treatments for chronic lymphocytic leukaemia. <b>2009</b> , 69, 2415-49	33

2247	Update in the management of chronic lymphocytic leukemia. <b>2009</b> , 2, 29		23
2246	Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. <i>Blood</i> , <b>2009</b> , 114, 5307-14	2.2	141
2245	Monoclonal B-cell lymphocytosis: definitions and natural history. <b>2009</b> , 50, 493-7		10
2244	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <b>2009</b> , 50, 1261-8		60
2243	Bendamustine in the treatment of chronic lymphocytic leukemia. <b>2009</b> , 9, 165-74		11
2242	Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. <b>2009</b> , 50, 863-4		12
2241	Monoclonal B lymphocytosis in the general population. <b>2009</b> , 50, 490-2		14
2240	Management of chronic lymphocytic leukemia: an update. <b>2009</b> , 6, 271-278		
2239	Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. <b>2009</b> , 27, 4378-84		349
2238	Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2009</b> , 113, 6496-7; author reply 6497-8	2.2	13
2237	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. <i>Blood</i> , <b>2009</b> , 114, 2044-50	2.2	120
2236	State-of-the-art treatment of chronic lymphocytic leukemia. <b>2009</b> , 440-9		49
2235	Predicting clinical outcome in CLL: how and why. <b>2009</b> , 421-9		47
2234	Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. <b>2009</b> , 27, 3994-4001		230
2233	Closer to the truth in AML. <i>Blood</i> , <b>2009</b> , 113, 4129-30	2.2	8
2232	Immune thrombocytopenia in lymphoproliferative disorders. <b>2009</b> , 23, 1261-74		21
2231	The leukemias of mature lymphocytes. <b>2009</b> , 23, 843-71		7
2230	Guidelines for an integrated diagnostic approach of chronic lymphoproliferative disorders in the routine laboratory of haematology in Belgium. <b>2009</b> , 64, 494-504		1

2229	The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?. <i>Blood</i> , <b>2009</b> , 113, 6495-6	2.2	8
2228	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , <b>2009</b> , 113, 4188-96	2.2	91
2227	The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. <i>Blood</i> , <b>2009</b> , 114, 26-32	2.2	107
2226	Dasatinib induces a response in chronic lymphocytic leukemia. <i>Blood</i> , <b>2009</b> , 113, 498	2.2	13
2225	The changing definition of CLL. <i>Blood</i> , <b>2009</b> , 113, 4130-1	2.2	1
2224	Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. <i>Blood</i> , <b>2009</b> , 114, 33-7	2.2	164
2223	High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. <i>Blood</i> , <b>2009</b> , 114, 4675-86	2.2	77
2222	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , <b>2009</b> , 114, 4696-702	2.2	95
2221	Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. <i>Blood</i> , <b>2009</b> , 114, 2581-8	2.2	32
2220	Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. <i>Blood</i> , <b>2009</b> , 114, 4460-8	2.2	58
2219	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. <i>Blood</i> , <b>2009</b> , 114, 3872-9	2.2	159
2218	Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. <i>Blood</i> , <b>2009</b> , 114, 4469-76	2.2	42
2217	Alemtuzumab for chronic lymphocytic leukaemia. <b>2009</b> ,		1
2216	Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. <b>2009</b> ,		1
2215	Familial chronic lymphocytic leukemia. <b>2010</b> , 17, 350-5		28
2214	The Classification of Lymphoma: Updating the WHO Classification. <b>2010</b> , 614-638		
2213	NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. <b>2010</b> , 8, 288-334		185
2212	High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. <b>2010</b> , 95, 1519-25		40



2211	Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. <b>2010</b> , 95, 2072-9		29
2210	Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. <b>2010</b> , 24, 803-10		26
2209	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 296-305	2.2	112
2208	Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 3726-36	2.2	40
2207	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 3079-88	2.2	39
2206	MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. <i>Blood</i> , <b>2010</b> , 115, 3949-59	2.2	92
2205	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. <i>Blood</i> , <b>2010</b> , 116, 945-52	2.2	173
2204	Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials. <i>Blood</i> , <b>2010</b> , 116, 1817; author reply 1817-8	2.2	
2203	Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. <i>Blood</i> , <b>2010</b> , 116, 2713-23	2.2	66
2202	Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 116, 2724-31	2.2	63
2201	Response: Defining response criteria in CLL patients treated in clinical research trials. <i>Blood</i> , <b>2010</b> , 116, 1817-1818	2.2	1
2200	Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. <i>Blood</i> , <b>2010</b> , 116, 5957-60	2.2	39
2199	Stage C or not stage C...?. <i>Blood</i> , <b>2010</b> , 116, 4735-6	2.2	1
2198	Chronic lymphocytic leukemia: putting new treatment options into perspective. <b>2010</b> , 17, 4-15; quiz 16		11
2197	Chronic Lymphocytic Leukaemia and Other B-Cell Disorders. <b>2010</b> , 530-557		1
2196	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <b>2010</b> , 51, 822-38		8
2195	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 116, 584-92	2.2	46
2194	Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma. <b>2010</b> , 89, 133-4		1

2193	Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. <b>2010</b> , 136, 403-10	9
2192	Chronic lymphocytic leukaemia Emerging treatment options: a report from the ASH Meeting 2009. <b>2010</b> , 3, 65-68	
2191	Mantle cell lymphoma and chronic lymphocytic leukemia: report of a rare disease association and review of the literature. <b>2010</b> , 3, 91-99	2
2190	p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine. <b>2010</b> , 3, 61-68	3
2189	Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. <b>2010</b> , 27, 820-5	11
2188	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. <b>2010</b> , 5, 45-51	3
2187	CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it?. <b>2010</b> , 20, 384-90	44
2186	Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. <b>2010</b> , 200, 170-4	8
2185	Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. <b>2010</b> , 38, 756-64, 764.e1-4	32
2184	Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. <b>2010</b> , 84, 310-5	7
2183	Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. <b>2010</b> , 84, 406-11	18
2182	MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. <b>2010</b> , 85, 251-6	14
2181	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. <b>2010</b> , 85, 314-20	22
2180	Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. <b>2010</b> , 49, 851-9	40
2179	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <b>2010</b> , 116, 4777-87	91
2178	Refining the white blood cell differential: the first flow cytometry routine application. <b>2010</b> , 77, 552-63	55
2177	Evolution of a precursor. <b>2010</b> , 78, 1-3	1
2176	Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). <b>2010</b> , 78 Suppl 1, S19-23	71

2175	Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. <b>2010</b> , 78 Suppl 1, S42-6	22
2174	Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics. <b>2010</b> , 78 Suppl 1, S24-34	33
2173	CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. <b>2010</b> , 78 Suppl 1, S35-41	22
2172	Monoclonal B cell lymphocytosis: clinical and population perspectives. <b>2010</b> , 78 Suppl 1, S115-9	6
2171	ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. <b>2010</b> , 85, 494-8	23
2170	Stability of measurement of the immature platelet fraction. <b>2010</b> , 85, 622-4	21
2169	Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. <b>2010</b> , 85, 611-3	73
2168	Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location. <b>2010</b> , 85, 613-6	49
2167	Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin. <b>2010</b> , 85, 624-6	3
2166	Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. <b>2010</b> , 85, 627-9	8
2165	Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. <b>2010</b> , 85, 616-9	16
2164	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <b>2010</b> , 85, 619-22	9
2163	What do healthcare providers ask their patients with immune thrombocytopenia?. <b>2010</b> , 85, 629-31	1
2162	Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient. <b>2010</b> , 85, 631-3	10
2161	Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. <b>2010</b> , 34, 335-9	9
2160	Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma. <b>2010</b> , 34, 580-4	11
2159	Lymphomas in the bone marrow. <b>2010</b> , 16, 125-142	2
2158	Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. <b>2010</b> , 24, 135-41	11

2157	Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. <b>2010</b> , 148, 484-6	11
2156	IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <b>2010</b> , 149, 299-302	1
2155	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. <b>2010</b> , 151, 152-8	50
2154	Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. <b>2010</b> , 103, 642-8	38
2153	Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. <b>2010</b> , 24, 133-40	50
2152	A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. <b>2010</b> , 24, 222-6	36
2151	The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. <b>2010</b> , 24, 226-9	10
2150	Changing paradigms in the treatment of chronic lymphocytic leukemia. <b>2010</b> , 24, 500-11	16
2149	Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. <b>2010</b> , 24, 512-20	166
2148	Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. <b>2010</b> , 24, 877-81	17
2147	Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. <b>2010</b> , 24, 798-805	36
2146	The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. <b>2010</b> , 24, 1152-9	81
2145	Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. <b>2010</b> , 24, 1310-6	44
2144	Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. <b>2010</b> , 24, 1317-24	42
2143	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <b>2010</b> , 42, 132-6	196
2142	From pathogenesis to treatment of chronic lymphocytic leukaemia. <b>2010</b> , 10, 37-50	438
2141	Management of chronic leukemia in older adults. 230-244	
2140	Blood Disorders in the Elderly. <b>2010</b> , 775-790	

2139	Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia. <b>2010</b> , 5, e15407		21
2138	Management of patients with chronic lymphocytic leukemia treated with lenalidomide. <b>2010</b> , 14, 491-9		7
2137	Signaling Targets in Lymphoid Leukemias. <b>2010</b> , 2831-2835		
2136	The spectrum of use of rituximab in chronic lymphocytic leukemia. <b>2010</b> , 3, 227-46		4
2135	First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. <b>2010</b> , 3, 53-67		14
2134	Allogeneic transplantation for chronic lymphocytic leukemia. <b>2010</b> , 2, e2010026		2
2133	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). <b>2010</b> , 1, 115-22		1
2132	The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. <b>2010</b> , 1, 1-8		4
2131	Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. <b>2010</b> , 16, 4382-91		45
2130	Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. <b>2010</b> , 16, 620-8		38
2129	Epigenetic inactivation of the miR-34a in hematological malignancies. <b>2010</b> , 31, 745-50		144
2128	How I treat autoimmune hemolytic anemias in adults. <i>Blood</i> , <b>2010</b> , 116, 1831-8	2.2	233
2127	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2010</b> , 21 Suppl 5, v162-4		14
2126	The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. <b>2010</b> , 21, 331-334		35
2125	Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia. <b>2010</b> , 124, 103-4		
2124	Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. <b>2010</b> , 24, 1572-82		17
2123	17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. <i>Blood</i> , <b>2010</b> , 116, 45-53	2.2	91
2122	The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. <b>2010</b> , 14, 27-32		12

2121	Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia. <b>2010</b> , 14, 19-26	2
2120	Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. <b>2010</b> , 51, 2222-9	25
2119	Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. <b>2010</b> , 28, 3015-22	158
2118	U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. <b>2010</b> , 16, 4331-8	82
2117	Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. <b>2010</b> , 107, 7479-84	95
2116	TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. <b>2010</b> , 184, 4761-9	43
2115	Standard of care and novel treatments for chronic lymphocytic leukemia. <b>2010</b> , 67, 1813-24	2
2114	Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. <b>2010</b> , 24, 2122-7	6
2113	Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia. <b>2010</b> , 2010,	5
2112	IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. <b>2010</b> , 24, 2120-2	31
2111	Understanding and managing ultra high-risk chronic lymphocytic leukemia. <b>2010</b> , 2010, 481-8	96
2110	Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. <b>2010</b> , 95, 1526-33	126
2109	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <b>2010</b> , 51, 95-106	13
2108	A systematic review on Richter syndrome: what is the published evidence?. <b>2010</b> , 51, 415-21	34
2107	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. <b>2010</b> , 95, 464-9	31
2106	Prognostic markers and stratification of chronic lymphocytic leukemia. <b>2010</b> , 2010, 77-81	31
2105	Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. <b>2010</b> , 2, 35-41	22
2104	Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. <b>2010</b> , 95, 1441-3	9

2103	Mature B- and T-cell Neoplasms and Hodgkin Lymphoma. <b>2010</b> , 297-374		1
2102	A case of acute myeloid leukemia initially treated as chronic lymphocytic leukemia: what do we know about t(4;12)(q12;p13)?. <b>2010</b> , 203, 348-51		4
2101	MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. <b>2010</b> , 9, 123		87
2100	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <b>2010</b> , 8, 23		15
2099	Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. <b>2010</b> , 70, 1445-76		144
2098	Ofatumumab. <b>2010</b> , 70, 1013-9		10
2097	Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. <b>2010</b> , 70, 261-72		38
2096	Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). <b>2010</b> , 10, 297-300		16
2095	Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. <b>2010</b> , 10, 361-8		18
2094	Chronic lymphocytic leukemia: new concepts for future therapy. <b>2010</b> , 10, 369-78		9
2093	Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study. <b>2010</b> , 10 Suppl 1, S34-41		2
2092	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 4191-7	2.2	86
2091	Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <b>2010</b> , 251-261		
2090	[Chronic lymphocytic leukemia]. <b>2010</b> , 135, 172-8		4
2089	Therapy of chronic lymphocytic leukaemia. <b>2010</b> , 23, 85-96		23
2088	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). <b>2010</b> , 23, 71-84		51
2087	Diagnostic issues in chronic lymphocytic leukaemia (CLL). <b>2010</b> , 23, 3-20		33
2086	Autoimmune complications in chronic lymphocytic leukaemia (CLL). <b>2010</b> , 23, 47-59		69

2085	Is MRD eradication a desirable goal in CLL?. <b>2010</b> , 23, 97-107		5
2084	Signalling to drug resistance in CLL. <b>2010</b> , 23, 121-31		20
2083	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. <b>2010</b> , 16, 871-90		85
2082	NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. <b>2010</b> , 16, 1325-46		29
2081	Activation-induced cytidine deaminase splicing patterns in chronic lymphocytic leukemia. <b>2010</b> , 44, 262-7		15
2080	Chemoimmunotherapy of chronic lymphocytic leukemia. <b>2010</b> , 7, 521-32		53
2079	Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. <i>Blood</i> , <b>2010</b> , 116, 4588-90	2.2	35
2078	TP53 mutation and survival in chronic lymphocytic leukemia. <b>2010</b> , 28, 4473-9		430
2077	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , <b>2010</b> , 116, 2438-47	2.2	240
2076	Immunoglobulin heavy chain V-D-J gene rearrangement and mutational status in Uruguayan patients with chronic lymphocytic leukemia. <b>2010</b> , 51, 2070-8		8
2075	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. <b>2010</b> , 376, 1164-74		1471
2074	How I treat CLL up front. <i>Blood</i> , <b>2010</b> , 115, 187-97	2.2	154
2073	Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. <b>2010</b> , 28, 1756-65		385
2072	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. <b>2010</b> , 11, 1149-59		565
2071	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Monoclonal B-Cell Lymphocytosis. <b>2010</b> , 3, 907-31		3
2070	Chronic lymphocytic leukemia. <b>2010</b> , 21 Suppl 7, vii154-64		32
2069	Chronic lymphocytic leukemia: planning for an aging population. <b>2010</b> , 10, 1389-94		30
2068	Monoclonal B cell lymphocytosis. <b>2010</b> , 51, 1386-8		6



2067	Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). <b>2010</b> , 51, 613-9		6
2066	Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia. <b>2010</b> , 51, 1767-70		1
2065	Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. <i>Blood</i> , <b>2010</b> , 115, 5041-52	2.2	89
2064	Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. <b>2010</b> , 51, 2230-9		17
2063	Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. <b>2010</b> , 51, 1485-93		10
2062	Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. <b>2011</b> , 52, 15-23		8
2061	Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia. <b>2011</b> , 52, 719-23		5
2060	Insight into the behavior of hairy cell leukemia by immunogenetic analysis. <b>2011</b> , 52 Suppl 2, 103-7		5
2059	TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia. <b>2011</b> , 52, 72-8		8
2058	Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. <b>2011</b> , 52, 79-84		14
2057	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , <b>2011</b> , 117, 3391-401	2.2	249
2056	T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. <b>2011</b> , 3, 95ra73		1656
2055	Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. <b>2011</b> , 4, 157-60		9
2054	Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab. <b>2011</b> , 126, 40-3		8
2053	Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. <b>2011</b> , 52, 1401-3		23
2052	Classificação da Organização Mundial da Saúde para os tumores dos tecidos hematopoético e linfóide, 4a edição, 2008 - principais modificações introduzidas em relação à 3a edição, 2001. <b>2011</b> , 57, 66-73		3
2051	World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001. <b>2011</b> , 57, 66-73		2
2050	Fatal paraneoplastic systemic leukocytoclastic vasculitis as a presenting feature of chronic lymphocytic leukemia. <b>2011</b> , 11 Suppl 1, S14-6		9

2049	3.2 Evolution of High-Sensitivity, Multi-Color Flow Cytometric Immunophenotyping for Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia: Peripheral Blood versus Bone Marrow?. <b>2011</b> , 11, S197		0
2048	5.11 Lenalidomide Consolidation Seems to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated Chronic Lymphocytic Leukemia. <b>2011</b> , 11, S249		
2047	5.12 Ofatumumab-Based Chemoimmunotherapy for Patients With Previously Untreated Chronic Lymphocytic Leukemia. <b>2011</b> , 11, S250		
2046	Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. <b>2012</b> , 40, 269-76		7
2045	Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. <b>2011</b> , 52, 1003-9		11
2044	[Spontaneous complete remission in two patients with chronic lymphocytic leukemia]. <b>2011</b> , 137, 238-9		
2043	Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. <b>2011</b> , 28, 163-76		30
2042	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , <b>2011</b> , 117, 5019-32	2.2	1356
2041	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. <b>2011</b> , 208, 1389-401		483
2040	High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. <b>2011</b> , 108, 21194-9		133
2039	The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. <b>2011</b> , 25, 1760-7		30
2038	Salvage therapy for relapsed chronic lymphocytic leukemia. <b>2011</b> , 4, 199-212		
2037	Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5(-) monoclonal B-cell lymphocytosis. <b>2011</b> , 204, 260-4		12
2036	Strength of evidence and handling uncertainty: practical considerations and general observations. <b>2011</b> , 64, 1272-4		
2035	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , <b>2011</b> , 118, 6904-8	2.2	298
2034	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 3072-2.	2.2	103
2033	Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. <b>2011</b> , 29, 3559-66		315
2032	Phase précoce de la leucémie lymphoïde chronique (LLC) et concept de lymphocytose B monoclonale (MBL). <b>2011</b> , 2011, 47-53		

2031	Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. <b>2011</b> , 29, 2703-8		76
2030	Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. <i>Blood</i> , <b>2011</b> , 117, 3016-24	2.2	152
2029	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 117, 6450-8	2.2	107
2028	Genetics of chronic lymphocytic leukemia. <b>2011</b> , 31, 649-58, ix		6
2027	Rituximab-containing therapy for chronic lymphocytic leukaemia [Authors' reply. <b>2011</b> , 377, 206		
2026	Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia. <b>2011</b> , 17, 834-9		5
2025	Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report. <b>2011</b> , 26, 824-8		8
2024	Chronic lymphocytic leukaemia with unusual morphologic features simulating the diagnosis of polyclonal lymphocytosis with binucleated lymphocytes. <b>2011</b> , 17, 89-92		1
2023	Practical aspects of allogeneic hematopoietic cell transplantation for patients with poor-risk chronic lymphocytic leukemia. <b>2011</b> , 11, 161-72		1
2022	Targeted treatment for chronic lymphocytic leukemia. <b>2011</b> , 4, 169-83		4
2021	Chronic lymphocytic leukemia--genomics lead the way. <b>2011</b> , 96, 1402-5		3
2020	[Practical considerations and questions in the treatment of chronic lymphocytic leukemia]. <b>2011</b> , 152, 958-63		
2019	Bendamustine for patients with B cell lymphoid malignancies. <b>2011</b> ,		0
2018	Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. <b>2011</b> , 6, e21018		63
2017	Epigenetic inactivation of the miR-124-1 in haematological malignancies. <b>2011</b> , 6, e19027		99
2016	Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. <b>2011</b> , 6, e24313		35
2015	Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. <b>2011</b> , 6, e24592		13
2014	Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. <b>2011</b> , 24, 915-23		19

2013	A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?. <b>2011</b> , 23, 455-60		15
2012	Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. <b>2011</b> , 96, 1144-52		65
2011	Signal transduction inhibitors in chronic lymphocytic leukemia. <b>2011</b> , 23, 601-8		13
2010	Chronic lymphocytic leukemia: the most common leukemia in adults. <b>2011</b> , 24, 54-8 Quiz 59		6
2009	Leucémie lymphoïde chronique : quand l'écouter, comment l'affirmer ? Quels en sont les traitements?. <b>2011</b> , 6, 1-6		
2008	Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. <b>2011</b> , 96, 1644-52		63
2007	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , <b>2011</b> , 117, 1817-21	2.2	32
2006	Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 117, 2668-80	2.2	41
2005	Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. <i>Blood</i> , <b>2011</b> , 117, 6109-19	2.2	56
2004	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 3489-98	2.2	145
2003	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 6353-61	2.2	32
2002	SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. <i>Blood</i> , <b>2011</b> , 118, 4150-8	2.2	92
2001	General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. <i>Blood</i> , <b>2011</b> , 118, 6618-25	2.2	112
2000	CD38 and chronic lymphocytic leukemia: a decade later. <i>Blood</i> , <b>2011</b> , 118, 3470-8	2.2	153
1999	?????. <b>2011</b> , 87, 66-82		
1998	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. <b>2011</b> , 96, 277-83		41
1997	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. <b>2011</b> , 96, 1153-60		39
1996	The European LeukemiaNet: achievements and perspectives. <b>2011</b> , 96, 156-62		12

1995	[Lymphoid malignancies: Progress in diagnosis and treatment. Topics: III. Diagnosis and treatment; 1. Management of acute lymphoblastic leukemia and chronic lymphocytic leukemia]. <b>2011</b> , 100, 1817-24	
1994	The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract. <b>2011</b> , 39, 965-72	4
1993	Small lymphocytic lymphoma in a patient with CREST syndrome. <b>2011</b> , 4, 132-5	3
1992	Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma. <b>2011</b> ,	1
1991	KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. <b>2011</b> , 78, 129-38	28
1990	Tumour-loaded $\beta$ -type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile. <b>2011</b> , 74, 318-326	20
1989	Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2011</b> , 102, 2103-7	25
1988	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <b>2011</b> , 152, 570-8	34
1987	Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. <b>2011</b> , 152, 295-306	103
1986	A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <b>2011</b> , 152, 284-94	22
1985	Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. <b>2011</b> , 153, 351-7	17
1984	A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 dysfunction. <b>2011</b> , 154, 271-4	3
1983	Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. <b>2011</b> , 154, 14-22	62
1982	Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. <b>2011</b> , 155, 519-21	6
1981	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <b>2011</b> , 154, 590-9	35
1980	Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. <b>2011</b> , 25, 473-8	53
1979	The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. <b>2011</b> , 25, 638-47	38
1978	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. <b>2011</b> , 15, 2760-7	79

1977	Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. <b>2011</b> , 86, 405-411	6
1976	A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia. <b>2011</b> , 87, 228-34	9
1975	Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. <b>2011</b> , 87, 426-33	20
1974	MicroRNAs in chronic lymphocytic leukemia. <b>2011</b> , 90, 173-8	9
1973	Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. <b>2011</b> , 80, 100-13	3
1972	NAD <sup>+</sup> -metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. <b>2011</b> , 585, 1514-20	16
1971	Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. <b>2011</b> , 20, 246-59	203
1970	Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. <b>2011</b> , 141, 58-66	21
1969	Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. <b>2011</b> , 49, 115-20	7
1968	Chronic lymphocytic leukemia in less fit patients: "slow-go". <b>2011</b> , 52, 2207-16	18
1967	Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. <b>2011</b> , 27, 1987-93	8
1966	Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. <b>2011</b> , 8, 38-47	128
1965	Differential and tumor-specific expression of CD160 in B-cell malignancies. <i>Blood</i> , <b>2011</b> , 118, 2174-83	2.2 37
1964	Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals. <b>2011</b> , 123, 269-75	
1963	2008-WHO-Klassifikation der malignen Lymphome im Jahr 2011. <b>2011</b> , 17, 769-788	0
1962	Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. <b>2011</b> , 90, 59-65	13
1961	The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). <b>2011</b> , 90, 709-17	28
1960	Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. <b>2011</b> , 90, 1123-9	9

1959	Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. <b>2011</b> , 90, 1131-6	12
1958	Immunologic aspects of monoclonal B-cell lymphocytosis. <b>2011</b> , 49, 269-80	10
1957	ASH update 2010: Chronic lymphocytic leukaemia. <b>2011</b> , 4, 117-119	0
1956	New insights into the pathobiology of chronic lymphocytic leukemia. <b>2011</b> , 4, 149-163	0
1955	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. <b>2011</b> , 4, 189-197	1
1954	Rituximab in chronic lymphocytic leukemia. <b>2011</b> , 28, 534-54	11
1953	S2-Leitlinie Humangenetische Diagnostik. <b>2011</b> , 23, 281-323	26
1952	What is the best frontline therapy for patients with CLL and 17p deletion?. <b>2011</b> , 6, 36-46	22
1951	Survival trends among 1,325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. <b>2011</b> , 86, 985-92	6
1950	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. <b>2011</b> , 86, 1007-12	37
1949	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <b>2011</b> , 50, 633-43	57
1948	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. <b>2011</b> , 50, 726-34	16
1947	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. <b>2011</b> , 117, 2163-9	42
1946	Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. <b>2011</b> , 117, 4679-88	76
1945	Methodological comparison of two anti-ZAP-70 antibodies. <b>2011</b> , 80, 300-8	8
1944	Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. <b>2011</b> , 80, 309-17	8
1943	No effect of lysis solutions on absolute CD19+ lymphocytes count and CD45 index in chronic lymphocytic leukemia. <b>2011</b> , 80, 369-72	4
1942	Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study. <b>2011</b> , 80, 346-53	11



1941	The detection of minimal residual disease status in chronic lymphocytic leukemia. <b>2011</b> , 80, 344-5	
1940	The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis. <b>2011</b> , 29, 22-30	3
1939	Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience. <b>2011</b> , 29, 107-10	2
1938	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <b>2011</b> , 29, 91-9	24
1937	Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. <b>2011</b> , 29, 55-66	30
1936	Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. <b>2011</b> , 129, 1162-9	12
1935	State of the art treatment of chronic lymphocytic leukaemia. <b>2011</b> , 25, 1-9	40
1934	Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. <b>2011</b> , 25, 91-6	34
1933	Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. <b>2011</b> , 35, 363-8	110
1932	TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. <b>2011</b> , 35, 272-4	38
1931	Transient marked increase in lymphocytosis during acute illness in chronic lymphocytic leukemia. <b>2011</b> , 35, e8-9	
1930	High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. <b>2011</b> , 35, 721-9	9
1929	Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: comparison with FISH. <b>2011</b> , 35, 1032-8	14
1928	Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. <b>2011</b> , 71, 4473-83	131
1927	Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. <b>2011</b> , 26, 2712-4	34
1926	Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2011</b> , 22 Suppl 6, vi50-4	109
1925	The novel NF- $\kappa$ B inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia. <b>2011</b> , 1, e12	19
1924	Monoclonal B-lymphocytosis: demographics, nature and subclassification in 414 community patients. <b>2011</b> , 52, 2293-8	11



1923	Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. <b>2011</b> , 96, 1161-9	74
1922	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <b>2011</b> , 52, 374-86	1
1921	White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. <b>2011</b> , 96, 626-30	24
1920	Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. <b>2011</b> , 7, 765-74	24
1919	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. <b>2011</b> , 52, 2064-8	13
1918	The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. <b>2011</b> , 52, 754-63	18
1917	Predictive markers and driving factors behind Richter syndrome development. <b>2011</b> , 11, 433-42	12
1916	Colonic perforation secondary to chronic lymphocytic leukemia infiltration without Richter transformation. <b>2011</b> , 52, 930-3	3
1915	Synchronous presentation of B-cell chronic lymphocytic leukemia/small-cell lymphoma and colon adenocarcinoma within the same mesenteric lymph nodes and a single liver metastasis. <b>2011</b> , 29, e11-3	4
1914	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. <b>2011</b> , 29, 4088-95	105
1913	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. <b>2011</b> , 29, 1349-55	113
1912	Treatment options for high-risk chronic lymphocytic leukaemia. <b>2011</b> , 2, 147-59	4
1911	Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas. <b>2011</b> , 2011, 960137	4
1910	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. <b>2011</b> , 5, 45-53	7
1909	The Antineoplastic Effect of Nitric Oxide-Donating Acetylsalicylic Acid (NO-ASA) in Chronic Lymphocytic Leukemia (CLL) Cells is Highly Dependent on its Positional Isomerism. <b>2011</b> , 2, 279-89	
1908	Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. <b>2011</b> , 2, 249-65	3
1907	Combination of cellular population data and CytoDiff analyses for the diagnosis of lymphocytosis. <b>2011</b> , 49, 1861-8	11
1906	Chronic lymphocytic leukemia and autoimmunity: a systematic review. <b>2011</b> , 96, 752-61	94

1905	Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. <b>2011</b> , 17, 286-93	16
1904	Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial. <b>2011</b> , 11, 1333-40	11
1903	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <b>2011</b> , 52, 1425-34	11
1902	Choosing first-line therapy for chronic lymphocytic leukemia. <b>2011</b> , 11, 1379-90	13
1901	Update on therapy of chronic lymphocytic leukemia. <b>2011</b> , 29, 544-50	88
1900	Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review. <b>2011</b> , 28, 86-96	
1899	A review of pharmacologic options for previously untreated chronic lymphocytic leukemia. <b>2011</b> , 17, 91-103	3
1898	[Fluorescence in situ hybridization in hematology]. <b>2012</b> , 69, 986-93	0
1897	Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. <b>2012</b> , 4, e2012053	11
1896	The spectrum of genetic defects in chronic lymphocytic leukemia. <b>2012</b> , 4, e2012076	9
1895	Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. <b>2012</b> , 2012, 756353	21
1894	The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. <b>2012</b> , 3, 224	48
1893	A case of chronic lymphocytic leukemia with massive ascites. <b>2012</b> , 4, e51	4
1892	Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. <b>2012</b> , 137, 75-85	32
1891	Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?. <b>2012</b> , 18, 396-403	36
1890	[Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia]. <b>2012</b> , 99, 1123-32	
1889	Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. <b>2012</b> , 3, 375-89	19
1888	Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2012</b> , 25, 237-45	56

1887	Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. <b>2012</b> , 53, 218-24	10
1886	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. <b>2012</b> , 7, 1435-42	29
1885	Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. <b>2012</b> , 53, 2321-5	11
1884	ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. <b>2012</b> , 97, 5-8	24
1883	Prognostic factors in CLL. <b>2012</b> , 1, S29-30	4
1882	Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. <b>2012</b> , 26, 373-6	14
1881	Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?. <b>2012</b> , 26, 1703-7	19
1880	Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. <b>2012</b> , 26, 1144-5	17
1879	The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. <b>2012</b> , 26, 2554-7	63
1878	Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. <b>2012</b> , 19, 336-44	5
1877	Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma. <b>2012</b> , 26, 1707-10	16
1876	Chronic lymphocytic leukemia: treatment of relapse. <b>2012</b> , 1, S31-2	1
1875	Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. <b>2012</b> , 26, 1348-55	77
1874	Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status. <b>2012</b> , 13, 1522-8	7
1873	An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. <b>2012</b> , 127, 149-51	4
1872	Chronic Lymphocytic Leukemia. <b>2012</b> , 85-101	
1871	State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia. <b>2012</b> , 6, 165-78	1
1870	MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders. <b>2012</b> , 2012, 603830	8

1869	Radio-opacity and incidental identified mechanical complications of totally implantable venous access devices placed in the chest. <b>2012</b> , 53, 1035-9	3
1868	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. <b>2012</b> , 97, 599-607	54
1867	Potential clinical impact of three-dimensional visualization for fluorescent in situ hybridization image analysis. <b>2012</b> , 17, 050501	0
1866	Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. <b>2012</b> , 35, 420-6	6
1865	Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. <b>2012</b> , 97, 428-36	20
1864	Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. <b>2012</b> , 97, 153-4	34
1863	Physical contact with endothelial cells through $\alpha$ - and $\beta$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <b>2012</b> , 97, 952-60	28
1862	Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia. <b>2012</b> , 7, 281-289	
1861	Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. <b>2012</b> , 24, 176-81	9
1860	Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. <b>2012</b> , 19, 18-25	28
1859	Clinical aspects of monoclonal B-cell lymphocytosis. <b>2012</b> , 19, 8-17	21
1858	Treatment of relapsed or refractory chronic lymphocytic leukemia. <b>2012</b> , 19, 37-53	22
1857	Front-line therapy for chronic lymphocytic leukemia. <b>2012</b> , 19, 26-36	4
1856	Newly discovered quick, non-invasive screening method of bone marrow malignancies including various leukemias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, & multiple myeloma by abnormality of small rectangular area within bone marrow organ representation areas of the face. <b>2012</b> , 37, 13-17	2
1855	Alemtuzumab for patients with chronic lymphocytic leukaemia. <b>2012</b> , CD008078	21
1854	Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. <b>2012</b> , 18, 3399-405	14
1853	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. <b>2012</b> , 97, 943-51	17
1852	Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. <b>2012</b> , 51, 3427-30	4

1851	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <b>2012</b> , 97, 437-41		151
1850	Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia. <b>2012</b> ,		
1849	The initial approach to patients with chronic lymphocytic leukemia diagnosed in day-to-day practice. <b>2012</b> , 1, 47-55		
1848	Trisomy 12 and elevated GLL1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. <i>Blood</i> , <b>2012</b> , 119, 997-1007	2.2	34
1847	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 2854-62	2.2	236
1846	Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. <i>Blood</i> , <b>2012</b> , 120, 2639-49	2.2	51
1845	Development of high-grade B-cell lymphoma concurrent with T-cell chronic lymphocytic leukemia in a dog. <b>2012</b> , 74, 677-80		4
1844	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 120, 3501-9	2.2	107
1843	Molecular pathogenesis of chronic lymphocytic leukemia. <b>2012</b> , 122, 3432-8		124
1842	Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. <b>2012</b> , 53, 1445-51		7
1841	Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. <b>2012</b> , 18, 417-31		32
1840	Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 3184-5	2.2	45
1839	Risk categories and refractory CLL in the era of chemoimmunotherapy. <i>Blood</i> , <b>2012</b> , 119, 4101-7	2.2	95
1838	Predicting survival in chronic lymphocytic leukemia. <b>2012</b> , 12, 393-403		15
1837	ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. <b>2012</b> , 18, 1979-91		57
1836	Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 120, 4684-91	2.2	124
1835	Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. <b>2012</b> , 30, 2820-2		160
1834	High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. <b>2012</b> , 87, E133		2

1833	Leucemia linfocítica crónica: sospecha y confirmación del diagnóstico; tratamiento. <b>2012</b> , 16, 1-7	
1832	Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. <b>2012</b> , 61, 1201-10	36
1831	[Bone marrow histology from the clinical point of view]. <b>2012</b> , 33, 490-5	1
1830	Regulation of CLL survival by hypoxia-inducible factor and its target genes. <b>2012</b> , 586, 2906-10	20
1829	Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology. <b>2012</b> , 208, 510-7	1
1828	[Chronic lymphocytic leukaemia presenting with specific cutaneous infiltrates in the absence of lymphocytosis: Two cases]. <b>2012</b> , 139, 641-6	2
1827	Analysis of ex vivo Apoptosis of B and T cells from Peripheral Blood and Bone Marrow of Patients with Chronic Lymphocytic Leukemia. <b>2012</b> , 43, 336-341	1
1826	Research imaging in an academic medical center. <b>2012</b> , 19, 762-71	6
1825	Nowe markery prognostyczne przewlekłej białaczki limfocytowej badane metodą immunofenotypizacji. <b>2012</b> , 43, 271-276	
1824	The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. <b>2012</b> , 53, 1367-75	11
1823	Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. <b>2012</b> , 53, 77-82	20
1822	Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. <b>2012</b> , 53, 1660-5	9
1821	Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. <b>2012</b> , 53, 1961-5	17
1820	Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. <b>2012</b> , 53, 1817-9	4
1819	Improving quality of life in chronic lymphocytic leukemia. <b>2012</b> , 53, 1247-8	2
1818	Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. <b>2012</b> , 53, 1749-56	19
1817	Monoclonal B-lymphocytosis: reflections and definitions. <b>2012</b> , 53, 1647-50	2
1816	p53 protein expression in chronic lymphocytic leukemia. <b>2012</b> , 53, 1282-8	5

1815	Molecular genetics of high-risk chronic lymphocytic leukemia. <b>2012</b> , 5, 593-602		13
1814	Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. <b>2012</b> , 26, 2508-16		15
1813	Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. <b>2012</b> , 53, 2218-27		40
1812	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. <i>Blood</i> , <b>2012</b> , 119, 6145-54	2.2	87
1811	The B-cell receptor signaling pathway as a therapeutic target in CLL. <i>Blood</i> , <b>2012</b> , 120, 1175-84	2.2	291
1810	Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. <b>2012</b> , 72, 4931-43		47
1809	Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. <i>Blood</i> , <b>2012</b> , 119, 4467-75	2.2	289
1808	Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. <b>2012</b> , 18, 5924-33		4
1807	Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. <b>2012</b> , 26, 15-23		13
1806	Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis. <b>2012</b> , 317, 144-9		21
1805	Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. <b>2012</b> , 48, 889-95		26
1804	Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. <b>2012</b> , 10, 161		75
1803	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. <b>2012</b> , 159, 541-64		89
1802	S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia. <b>2012</b> , 103, 2056-63		18
1801	Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation. <b>2012</b> , 42, 1355-8		6
1800	Rituximab: current status as therapy for malignant and benign hematologic disorders. <b>2012</b> , 26, 71-82		14
1799	Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. <b>2012</b> , 72, 1929-50		15
1798	Hematological Cancers. <b>2012</b> , 279-325		

1797	Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality. <b>2012</b> , 205, 523-7	8
1796	IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia. <b>2012</b> , 12, 201-6	10
1795	Chronic lymphocytic leukemia in 2012. <b>2012</b> , 9, S26-S29	
1794	Managing the patient with chronic lymphocytic leukemia: initial evaluation and first-line treatment decisions. <b>2012</b> , 9, S77-S84	1
1793	Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. <b>2012</b> , 9, S85-S92	5
1792	Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. <b>2012</b> , 48, 3319-27	104
1791	Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. <b>2012</b> , 36, 1134-40	
1790	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <b>2012</b> , 36, 1278-82	24
1789	Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. <b>2012</b> , 11, CD008079	25
1788	Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. <b>2012</b> , 29, 3561-9	40
1787	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. <b>2012</b> , 26, 764-8	1
1786	The assessment of minimal residual disease in chronic lymphocytic leukaemia: comparison of multi-colour flow cytometry and bone marrow trephine biopsy. <b>2012</b> , 5, 305-309	
1785	Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study. <b>2012</b> , 64, 412-20	5
1784	Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. <b>2012</b> , 53, 1023-31	28
1783	Stem Cells and Cancer Stem Cells, Volume 6. <b>2012</b> ,	2
1782	Moderne Diagnostik bei akuten und chronischen Leukämien. <b>2012</b> , 18, 1073-1083	0
1781	Chronische lymphatische Leukämie. <b>2012</b> , 18, 1115-1119	0
1780	Cell surface expression of CD25 antigen (surface IL-2 receptor $\beta$ -chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients. <b>2012</b> , 91, 1597-602	5



1779	Bone Marrow Lymphoid Infiltrates. <b>2012,</b>	1
1778	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. <b>2012,</b> CD009045	4
1777	Leukemia and Related Disorders. <b>2012,</b>	3
1776	Molecular Aspects of Hematologic Malignancies. <b>2012,</b>	2
1775	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <b>2012,</b> 53, 1743-8	14
1774	Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. <b>2012,</b> 7, e34347	33
1773	DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl Nuclear Power Plant accident. <b>2012,</b> 53, 497-503	11
1772	Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus. <b>2012,</b>	
1771	Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. <b>2012,</b> 18, 1281-91	56
1770	Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. <b>2012,</b> 16, 474-9	1
1769	Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypy. <b>2012,</b> 18, 138-45	8
1768	Treatment and management of chronic lymphocytic leukemia in the elderly: what the pharmacist clinician should know. <b>2012,</b> 27, 274-85	1
1767	Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. <b>2012,</b> 2012, 88-96	30
1766	Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia. <b>2012,</b>	
1765	PharmaForum. <b>2012,</b> 35, 530-533	
1764	CD38 (CD38 molecule). <b>2012,</b>	
1763	The Chronic Leukemias. <b>2012,</b> 1209-1218	7
1762	T-Cell Prolymphocytic Leukemia Accompanied by Plural M-Proteins with Myelodysplastic Syndroxme in a Nonagenarian. <b>2012,</b> 02,	

1761	Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study. <b>2012</b> , 3, 354-61		3
1760	Chronic Lymphocytic Leukemia: Allogeneic Stem Cell Transplantation. <b>2012</b> , 353-364		
1759	Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. <b>2012</b> , 30, 980-8		334
1758	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. <i>Blood</i> , <b>2012</b> , 119, 2709-20	2.2	1110
1757	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 521-9	2.2	337
1756	Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. <b>2012</b> , 53, 2105-15		4
1755	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. <b>2012</b> , 30, 1647-55		140
1754	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. <b>2012</b> , 33, 1294-301		145
1753	miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. <b>2012</b> , 72, 1763-72		161
1752	Molecular genetic characterization of lymphoma: application to cytology diagnosis. <b>2012</b> , 40, 542-55		20
1751	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <b>2012</b> , 30, 46-9		18
1750	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. <b>2012</b> , 26, 1908-75		557
1749	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <b>2012</b> , 30, 488-96		622
1748	Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. <b>2012</b> , 30, 3209-16		332
1747	A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. <b>2012</b> , 87, 628-31		29
1746	Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets. <b>2012</b> , 87, 721-4		9
1745	Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. <b>2012</b> , 87, 737-40		21
1744	Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). <b>2012</b> , 118, 1827-37		30

1743	Case study interpretation--Portland: Case 1. Hairy cell leukemia with CLL-like monoclonal B lymphocytosis. <b>2012</b> , 82, 177-9		3
1742	Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. <b>2012</b> , 72, 2937-48		36
1741	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. <b>2012</b> , 97, 56-63		43
1740	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. <i>Blood</i> , <b>2012</b> , 120, 1262-73	2.2	80
1739	Up-regulated estrogen receptor $\alpha$ in chronic lymphocytic leukemia. <b>2012</b> , 53, 139-44		24
1738	RNA-based markers as prognostic factors in chronic lymphocytic leukemia. <b>2012</b> , 5, 69-79		8
1737	Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. <b>2012</b> , 18, 1870-8		23
1736	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. <i>Blood</i> , <b>2012</b> , 119, 2310-3	2.2	57
1735	Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. <b>2012</b> , 53, 362-70		5
1734	ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. <b>2012</b> , 26, 1458-61		154
1733	Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. <b>2012</b> , 32, 632-46		33
1732	Overexpression of Fc $\mu$ receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients. <b>2012</b> , 29, 1068-72		9
1731	IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group. <b>2012</b> , 29, 1093-101		8
1730	Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. <b>2012</b> , 61, 865-79		37
1729	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. <b>2012</b> , 91, 863-73		56
1728	Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. <b>2012</b> , 91, 1271-9		32
1727	Immunological aspects in chronic lymphocytic leukemia (CLL) development. <b>2012</b> , 91, 981-96		32
1726	Detection methods of ZAP-70 in chronic lymphocytic leukemia. <b>2012</b> , 12, 69-77		13

1725	Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. <b>2012</b> , 156, 50-66	84
1724	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <b>2012</b> , 156, 499-507	38
1723	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. <b>2012</b> , 21, 694-708	100
1722	Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation. <b>2012</b> , 88, 269-72	6
1721	High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. <b>2012</b> , 89, 72-80	19
1720	Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). <b>2012</b> , 36, 443-7	19
1719	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. <b>2012</b> , 36, 709-14	8
1718	Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. <b>2012</b> , 103, 875-81	43
1717	Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. <b>2012</b> , 157, 86-96	42
1716	Search for an aetiological virus candidate in chronic lymphocytic leukaemia by extensive transcriptome analysis. <b>2012</b> , 157, 709-17	6
1715	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <b>2012</b> , 158, 108-19	33
1714	Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <b>2012</b> , 158, 426-9	70
1713	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. <b>2012</b> , 158, 174-185	22
1712	In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. <b>2012</b> , 158, 489-98	18
1711	Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia. <b>2012</b> , 42, 846-8	1
1710	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <b>2012</b> , 10, 18	18
1709	Combined normal donor and CLL: Single tube ZAP-70 analysis. <b>2012</b> , 82, 67-77	4
1708	MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. <b>2012</b> , 130, 2054-61	21

1707	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. <b>2012</b> , 87, 361-7	11
1706	Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?. <b>2012</b> , 7, 3-12	13
1705	Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2012</b> , 29, 178-86	2
1704	Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. <b>2013</b> , 31, 54-5	24
1703	Novel agents for chronic lymphocytic leukemia. <b>2013</b> , 6, 36	25
1702	Epigenetic inactivation of the MIR129-2 in hematological malignancies. <b>2013</b> , 6, 16	50
1701	Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. <b>2013</b> , 34, 2031-9	40
1700	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. <b>2013</b> , 88, 803-16	124
1699	Lymphoma. <b>2013</b> ,	1
1698	Cancer Genomics. <b>2013</b> ,	4
1697	Next-generation sequencing of cancer consensus genes in lymphoma. <b>2013</b> , 54, 1831-5	8
1696	MBL versus CLL: how important is the distinction?. <b>2013</b> , 27, 251-65	9
1695	The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?. <b>2013</b> , 27, 267-88	34
1694	17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach. <b>2013</b> , 27, 289-301	10
1693	Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. <b>2013</b> , 27, 329-39	7
1692	The evolving role of stem cell transplantation in chronic lymphocytic leukemia. <b>2013</b> , 27, 355-69	11
1691	BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. <b>2013</b> , 32, 358-76	35
1690	Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia. <b>2013</b> , 13, 87	8

1689	NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. <b>2013</b> , 13, 274	23
1688	Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. <b>2013</b> , 109, 1287-90	28
1687	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. <b>2013</b> , 21, 2853-60	21
1686	Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. <b>2013</b> , 15, 196-209	20
1685	Monoclonal B cell lymphocytosis--what does it really mean?. <b>2013</b> , 8, 52-9	14
1684	A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. <b>2013</b> , 98, 164-70	10
1683	Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. <b>2013</b> , 97, 403-8	16
1682	Chronic lymphocytic leukemia: inception to cure: are we there?. <b>2013</b> , 29, 1-10	4
1681	Novel Molecular Acquisitions in Leukemias. <b>2013</b> , 453-493	
1680	Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. <b>2013</b> , 27, 170-82	116
1679	Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. <b>2013</b> , 92, 249-54	5
1678	Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. <b>2013</b> , 72, 709-13	13
1677	Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. <b>2013</b> , 71, 581-91	37
1676	Treatment of chronic lymphocytic leukemia. <b>2013</b> , 49, 44-50	
1675	Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. <b>2013</b> , 132, 1940-53	37
1674	Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. <b>2013</b> , 163, 182-93	17
1673	Cutaneous presentation of chronic lymphocytic leukemia as unique extramedullar involvement in a patient with normal peripheral blood lymphocyte count (monoclonal B-cell lymphocytosis). <b>2013</b> , 40, 740-4	9
1672	Ocena ekspresji cząsteczki CD1d na limfocytach B u chorych na przewlekłą limfocytową	
	<b>2013</b> , 44, 326-332	

1671	Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. <b>2013</b> , 54, 1817-20	14
1670	Targeting inflammatory pathways in chronic lymphocytic leukemia. <b>2013</b> , 88, 655-66	22
1669	Place de la cytométrie en flux dans le diagnostic et le suivi des syndromes lymphoprolifératifs B. <b>2013</b> , 2013, 37-48	
1668	LLC: physiopathologie, diagnostic et approche thérapeutique. <b>2013</b> , 2013, 61-71	
1667	The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia. <b>2013</b> , 6, 543-6	2
1666	Molecular bases of chronic lymphocytic leukemia in light of new treatments. <b>2013</b> , 155, 51-5	10
1665	First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. <b>2013</b> , 4, 141-7	8
1664	Blood microvesicles during chronic lymphoproliferative diseases. <b>2013</b> , 156, 94-7	10
1663	Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. <b>2013</b> , 31, 584-91	127
1662	Chronic leukemia. <b>2013</b> , 25, 459-70, vi	1
1661	Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia. <b>2013</b> , 41, 615-26	14
1660	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. <b>2013</b> , 210, 2273-88	195
1659	Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. <b>2013</b> , 62, 439-45	15
1658	Molecular biomarkers in chronic lymphocytic leukemia. <b>2013</b> , 792, 193-214	10
1657	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <b>2013</b> , 24, 1378-84	13
1656	Nouveautés sur les hémopathies lymphoïdes chroniques B matures. <b>2013</b> , 28, 174-182	
1655	How I treat patients with relapsed chronic lymphocytic leukaemia. <b>2013</b> , 163, 423-35	4
1654	Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. <b>2013</b> , 119, 3805-11	48

1653	Genetic susceptibility to chronic lymphocytic leukemia. <b>2013</b> , 50, 296-302	23
1652	Chronic lymphocytic leukaemia. <b>2013</b> , 41, 278-281	
1651	Abstracts of the Lectures During Haematocon 2013. <b>2013</b> , 29, 191-277	1
1650	Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells. <b>2013</b> , 2, 23	3
1649	[Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis]. <b>2013</b> , 54, 709-14	1
1648	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFB pathway. <b>2013</b> , 12, 173	60
1647	Chronic lymphocytic leukemia in Kenya: an immunophenotypic and clinicopathologic study. <b>2013</b> , 5, 192-197	2
1646	Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. <b>2013</b> , 6, 429-39	8
1645	High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. <b>2013</b> , 104, 996-1001	11
1644	Treatment of elderly patients with chronic lymphocytic leukemia: an unmet clinical need. <b>2013</b> , 6, 441-9	4
1643	Advances in Chronic Lymphocytic Leukemia. <b>2013</b> ,	2
1642	Towards targeted therapy of chronic lymphocytic leukemia. <b>2013</b> , 792, 259-91	10
1641	[National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Española de Hematología y Hemoterapia and Grupo Español de Leucemia Linfocítica Crónica]. <b>2013</b> , 141, 175.e1-8	4
1640	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. <b>2013</b> , 13, 169-82	19
1639	Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. <b>2013</b> , 8, 1-6	68
1638	Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. <b>2013</b> , 54, 790-3	2
1637	Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. <b>2013</b> , 54, 1268-78	12
1636	Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. <b>2013</b> , 54, 99-104	68



1635	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. <b>2013</b> , 88, 539-44		7
1634	Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. <b>2013</b> , 57, 527-35		16
1633	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. <b>2013</b> , 5, 47		35
1632	Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia. <b>2013</b> , 54, 1159-64		11
1631	CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 122, 4253-8	2.2	26
1630	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. <b>2013</b> , 160, 171-6		173
1629	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <b>2013</b> , 24, 561-76		162
1628	Multiple Myeloma. <b>2013</b> , 189-237		
1627	A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. <b>2013</b> , 84, 96-103		19
1626	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 1403-12	2.2	357
1625	Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. <b>2013</b> , 27, 1172-4		44
1624	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <b>2013</b> , 152, 714-26		1006
1623	Viral infections and their management in patients with chronic lymphocytic leukemia. <b>2013</b> , 54, 1602-13		24
1622	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. <b>2013</b> , 88, 24-31		21
1621	Intracellular cytokine expression in T cells from patients with chronic lymphocytic leukemia. <b>2013</b> , 44, 319-325		
1620	Richter's syndrome: Utility of 18F-FDG PET/CT. <b>2013</b> , 32, 102-104		
1619	Cyclophosphamide, alvociclib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. <b>2013</b> , 37, 1195-9		23
1618	Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. <b>2013</b> , 19, 82-6		5

1617	The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. <b>2013</b> , 37, 802-8	13
1616	Przewlekła białaczka limfocytowa u ludzi starszych. <b>2013</b> , 44, 93-98	2
1615	Richter's syndrome: Utility of $^{18}$ F-FDG PET/CT. <b>2013</b> , 32, 102-4	1
1614	Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series. <b>2013</b> , 13, e15-7	2
1613	Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?. <b>2013</b> , 13, 441-6	10
1612	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. <b>2013</b> , 37, 943-7	7
1611	Contribution of MLPA to routine diagnostic testing of recurrent genomic aberrations in chronic lymphocytic leukemia. <b>2013</b> , 206, 19-25	18
1610	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. <b>2013</b> , 19, 1087-93	11
1609	Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. <b>2013</b> , 37, 1222-8	18
1608	The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. <b>2013</b> , 37, 614-8	6
1607	Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins. <b>2013</b> , 41, 675-86	16
1606	Targeted therapy in chronic lymphocytic leukemia: past, present, and future. <b>2013</b> , 35, 1258-70	31
1605	Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. <b>2013</b> , 30, 405	13
1604	VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. <b>2013</b> , 30, 456	4
1603	New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works. <b>2013</b> , 54, 1876-81	4
1602	Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. <b>2013</b> , 160, 415-8	12
1601	Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. <b>2013</b> , 54, 2351-64	48
1600	Emerging drug profile: cyclin-dependent kinase inhibitors. <b>2013</b> , 54, 2133-43	53

1599	What do we do with chronic lymphocytic leukemia with 17p deletion?. <b>2013</b> , 8, 81-90	6
1598	Histopathology, Morphology and Immunophenotyping of CLL. <b>2013</b> , 71-89	
1597	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. <b>2013</b> , 103-119	
1596	Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. <b>2013</b> , 34, 929-40	53
1595	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. <b>2013</b> , 88, 277-82	11
1594	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. <b>2013</b> , 206, 49-62	51
1593	Recent advances in microRNA-mediated gene regulation in chronic lymphocytic leukemia. <b>2013</b> , 46, 901-8	4
1592	Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). <b>2013</b> , 37, 809-15	10
1591	The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal. <b>2013</b> , 54, 2377-84	5
1590	Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. <b>2013</b> , 27, 1659-65	110
1589	Differences and similarities between LC-MS derived serum fingerprints of patients with B-cell malignancies. <b>2013</b> , 34, n/a-n/a	2
1588	Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia. <b>2013</b> , 13, 447-457.e2	13
1587	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. <b>2013</b> , 88, 289-93	15
1586	Early neoplastic lymphoid lesions. <b>2013</b> , 30, 146-55	7
1585	Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. <b>2013</b> , 88, 647-51	35
1584	The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI. <b>2013</b> , 10, 2490-501	29
1583	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <b>2013</b> , 27, 1100-6	135
1582	Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. <b>2013</b> , 27, 2196-9	78

1581	Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. <b>2013</b> , 39, 340-9	12
1580	The changing paradigm of chronic lymphocytic leukemia management. <b>2013</b> , 24, 401-10	7
1579	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <b>2013</b> , 369, 32-42	1656
1578	The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells. <b>2013</b> , 54, 2712-9	8
1577	Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma. <b>2013</b> , 17, 937-49	17
1576	PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. <b>2013</b> , 27, 1090-9	55
1575	Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. <b>2013</b> , 19, 5890-900	50
1574	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <b>2013</b> , 6, 83	14
1573	[Chronic lymphocytic leukemia. Treatment and genetic risk profile]. <b>2013</b> , 54, 164, 166-70	8
1572	B-cell receptor signaling as a driver of lymphoma development and evolution. <b>2013</b> , 23, 410-21	142
1571	Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. <b>2013</b> , 14, 749-59	38
1570	Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. <b>2013</b> , 27, 142-9	139
1569	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. <b>2013</b> , 31, 88-94	858
1568	Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. <b>2013</b> , 54, 934-9	5
1567	450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. <b>2013</b> , 27, 150-8	86
1566	Chronic lymphocytic leukaemia in the cat: 18 cases (2000-2010). <b>2013</b> , 11, 256-64	24
1565	Role of microRNAs in chronic lymphocytic leukemia (Review). <b>2013</b> , 8, 719-25	12
1564	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <b>2013</b> , 98, 675-85	58

1563 B-cell chronic lymphocytic leukemia/lymphoma. **2013**, 196-214

1562 Nodal and leukemic small B-cell neoplasms. **2013**, 26 Suppl 1, S15-28

9

1561 The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. **2013**, 98, 1115-23

71

1560 Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. **2013**, 2013, 158-67

47

1559 BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. **2013**, 21, 1413-23

24

1558 [Chronic lymphocytic leukemia]. **2013**, 138, 2153-66

4

1557 Chronische lymphatische Leukämie - Standardtherapien und vielversprechende neue Behandlungsansätze. **2013**, 42, 350-354

1556 Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. **2013**, 98, 1259-63

8

1555 A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. **2013**, 98, 964-70

10

1554 Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. **2013**, 54, 476-82

10

1553 New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. **2013**, 2013, 740615

16

1552 Scalable system for classification of white blood cells from Leishman stained blood stain images. **2013**, 4, S15

35

1551 Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience. **2013**, 5, e2013031

11

1550 Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. **2013**, 31, 121-31

41

1549 The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. **2013**, 5, e2013027

3

1548 Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia. **2013**, 2013, 715391

5

1547 p110 $\alpha$  PI3 kinase pathway: emerging roles in cancer. **2013**, 3, 40

36

1546 Precursors to lymphoproliferative malignancies. **2013**, 22, 533-9

13

1545	Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis. <b>2013</b> , 59, 280-9	4
1544	In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. <b>2013</b> , 19, 367-79	31
1543	The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF- $\kappa$ B response in chronic lymphocytic leukemia cells. <b>2013</b> , 19, 2406-19	28
1542	Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. <b>2013</b> , 4, 157-71	8
1541	Richter syndrome. <b>2013</b> , 792, 173-91	23
1540	[Major therapeutic advances and new perspectives in onco-hematology]. <b>2013</b> , 100, 587-99	8
1539	Hämatologische Labordiagnostik im interdisziplinären hämatologischen Kompetenzzentrum (IHK) der hämatologisch onkologischen Klinik V der Universität Innsbruck und des Zentrallabors der Universität Innsbruck/Laboratory examination of hematologic diseases in the Interdiscipline Hematologic Competence Center (IHK) of Innsbruck of the Clinic for Hemato-oncology V of the University Hospital Innsbruck and the Central Laboratory of the University Hospital Innsbruck (ZIMCL)1. <b>2013</b> , 37,	
1538	Laboratory examination of hematologic diseases at the interdisciplinary hematologic competence center (IHK) of Innsbruck of the clinic for hemato-oncology V of the university hospital Innsbruck and the central laboratory of the university hospital Innsbruck (ZIMCL)1. <b>2013</b> , 37,	
1537	Monoclonal Antibodies in Oncology. <b>2013</b> ,	
1536	Novel monoclonal antibody-based therapies for leukemia. <b>2013</b> , 54-77	3
1535	Complete blood counts with differential: more accurate reference ranges based on circadian leukocyte trafficking. <b>2013</b> , 66, 909-10	2
1534	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <b>2013</b> , 160, 640-8	29
1533	Prognostic significance of serum free light chains in chronic lymphocytic leukemia. <b>2013</b> , 2013, 359071	5
1532	Spontaneous retroperitoneal hemorrhage in a patient with prolymphocytic transformation of chronic lymphocytic leukemia. <b>2013</b> , 2013, 802376	0
1531	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. <b>2013</b> , 163, 47-54	11
1530	Bcl-2 level as a biomarker for 13q14 deletion in CLL. <b>2013</b> , 84, 237-47	9
1529	Monoclonal B lymphocytosis versus chronic lymphocytic leukemia: factors affecting implementation of an absolute threshold. <b>2013</b> , 84, 149-56	2
1528	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. <b>2013</b> , 119, 1177-85	12

1527	Leukaemias into the 21st century. Part 2: the chronic leukaemias. <b>2013</b> , 43, 484-94	11
1526	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. <b>2013</b> , 90, 479-85	11
1525	Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <b>2013</b> , 88, 955-60	14
1524	Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH. <b>2013</b> , 31, 136-42	11
1523	MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. <b>2013</b> , 54, 2016-22	24
1522	ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia. <b>2013</b> , 54, 1171-6	3
1521	Technical issues: flow cytometry and rare event analysis. <b>2013</b> , 35, 344-50	47
1520	Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). <b>2013</b> , 119, 3788-96	40
1519	Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. <b>2013</b> , 90, 340-4	2
1518	The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. <b>2013</b> , 13, 1089-108	
1517	ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <b>2013</b> , 8, 720-9	23
1516	Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. <b>2013</b> , 54, 1012-9	34
1515	A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. <b>2013</b> , 8, 1280-8	33
1514	Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. <b>2013</b> , 139, 708-12	9
1513	Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. <b>2013</b> , 27, 1920-3	18
1512	Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. <b>2013</b> , 27, 1949-52	27
1511	Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B. <b>2013</b> , 3, e153	12
1510	Ibrutinib for the treatment of chronic lymphocytic leukemia. <b>2013</b> , 1, 925-933	2

1509	Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases. <b>2013</b> , 14, 6-12		5
1508	Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. <b>2013</b> , 9, 331-347		
1507	Genetic differences between Asian and Caucasian chronic lymphocytic leukemia. <b>2013</b> , 43, 561-5		12
1506	Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China. <b>2013</b> , 5, 1266-1272		7
1505	Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. <b>2013</b> , 26, 117-25		27
1504	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 1175-83	2.2	32
1503	CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 4126-36	2.2	50
1502	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). <i>Blood</i> , <b>2013</b> , 121, 4137-41	2.2	72
1501	Targeting B-cell anergy in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 3879-88, S1-8	2.2	63
1500	Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 122, 734-7	2.2	62
1499	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2013</b> , 122, 4129-39	2.2	445
1498	Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. <b>2013</b> , 98, 626-34		25
1497	Soluble CD23 measurement by CBA: A convenient and reliable quantification method in Chronic Lymphocytic Leukemia. <b>2013</b> ,		1
1496	Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <b>2013</b> , 31, 88-95		20
1495	Patients' needs in hematology: whose perspectives?. <b>2013</b> , 98, 828-30		6
1494	2012 SFH Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia (CLL). <b>2013</b> , 19, 4-9		
1493	Recent advances in the treatment of non-Hodgkin's lymphomas. <b>2013</b> , 11, 671-5		9
1492	[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 5. Diagnosis and treatment of chronic lymphocytic leukemia]. <b>2013</b> , 102, 1720-7		1



1491 Chronic lymphoid leukemia. **2013**, 19, 409-415

1490 Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. **2013**, 5, 225-33

19

1489 Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. **2013**, 8, 37-45

13

1488 Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. **2013**, 16, 231-7

5

1487 Small lymphocytic lymphoma/chronic lymphocytic leukemia. 121-137

1486 Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. **2013**, 19, 115-23

42

1485 Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence. **2013**, 19, 230-6

11

1484 CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF- $\kappa$ B activation. **2013**, 8, e64425

11

1483 Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. **2013**, 8, e72107

22

1482 Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. **2013**, 8, e78091

42

1481 The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. **2013**, 8, e78339

43

1480 Autoimmune cytopenias in chronic lymphocytic leukemia. **2013**, 2013, 730131

9

1479 Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths. **2013**, 5, e2013068

9

1478 Monoclonal Immunoglobulin. **2013**,

0

1477 PharmaForum. **2014**, 37, 784-787

1476 Molecular Pathology of Chronic Lymphocytic Leukemia and Relevance to Novel Therapies. **2014**, 1664-1676

1475 Coexistence of primary myelofibrosis and chronic lymphocytic leukemia. **2014**, 101

1474 Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options. **2014**, 9

0

1473	Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. <b>2014</b> , 9, e98818	28
1472	Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report. <b>2014</b> , 9, e114966	50
1471	Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemia. <b>2014</b> , 28, 131-4	6
1470	Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. <b>2014</b> , 2014, 435983	92
1469	Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. <b>2013</b> , 11, 265-71	8
1468	MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. <b>2014</b> , 2, 158-64	16
1467	Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. <b>2015</b> , 8, 1-7	3
1466	Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia. <b>2014</b> , 18, 29-33	5
1465	An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4. <b>2015</b> , 20, 720-8	4
1464	. <b>2014</b> ,	7
1463	Obinutuzumab for chronic lymphocytic leukemia. <b>2014</b> , 7, 533-43	8
1462	Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia. <b>2014</b> , 55, 2699-705	7
1461	Dual effect of oxidative stress on leukemia cancer induction and treatment. <b>2014</b> , 33, 106	76
1460	[Chronic lymphocytic leukemia: current standards and novel approaches]. <b>2014</b> , 55, 1400, 1402-4, 1406-9	
1459	Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH). <b>2014</b> , 7, 79	24
1458	microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. <b>2014</b> , 9, 910-7	35
1457	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. <b>2014</b> , 10, 957-67	92
1456	Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. <b>2014</b> , 4, e258	10

1455	CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL). <b>2014</b> , 100, 545-53	4
1454	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. <b>2014</b> , 55, 2739-47	8
1453	Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. <b>2014</b> , 3, 145-152	1
1452	Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia. <b>2014</b> , 2014, 686392	9
1451	On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. <b>2014</b> , 20, 4861-72	5 <sup>1</sup>
1450	Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines. <b>2014</b> , 7, 691-5	7
1449	The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. <b>2014</b> , 25, 200-6	25
1448	Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where. <b>2014</b> , 55, 233-4	6
1447	BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. <b>2014</b> , 2014, 125-34	26
1446	FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. <b>2014</b> , 120, 3494-501	4
1445	Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. <b>2014</b> , 28, 230-3	43
1444	Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia. <b>2014</b> , 2014, 159632	9
1443	Idelalisib for the treatment of chronic lymphocytic leukemia. <b>2014</b> , 2014, 931858	3
1442	Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. <b>2014</b> , 2014, 265840	4 <sup>1</sup>
1441	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. <b>2014</b> , 99, 1350-5	55
1440	Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. <b>2014</b> , 21, 124-7	2
1439	Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. <b>2014</b> , 86, 410-7	7
1438	Chronic lymphocytic leukemia in young (≤5 years) patients: a comprehensive analysis of prognostic factors and outcomes. <b>2014</b> , 99, 140-7	47

1437	Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies. <b>2014</b> , 55, 1067-75	18
1436	Chemoimmunotherapy for chronic lymphocytic leukemia. Author reply. <b>2014</b> , 370, 2348-9	4
1435	2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. <b>2014</b> , 55, 314-9	43
1434	Genetic risk of chronic lymphocytic leukemia: a tale of two cities. <b>2014</b> , 55, 735-6	1
1433	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2014</b> , 55, 2079-84	34
1432	Expression of PIM1 protein in chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2014</b> , 55, 2658-9	2
1431	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <b>2014</b> , 99, 873-80	28
1430	Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. <b>2014</b> , 35, 105-20	0
1429	Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. <b>2014</b> , 99, 7-18	40
1428	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. <b>2014</b> , 99, 881-7	25
1427	Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. <b>2014</b> , 99, 329-38	28
1426	Management of chronic lymphocytic leukemia in elderly patients. <b>2014</b> , 3, 433-443	
1425	Adult advanced chronic lymphocytic leukemia: computational analysis of whole-body CT documents a bone structure alteration. <b>2014</b> , 271, 805-13	14
1424	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <b>2014</b> , 89, 757-65	28
1423	Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility. <b>2014</b> , 32, 981-93	7
1422	New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. <b>2014</b> , 20, 5869-74	43
1421	Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. <b>2014</b> , 89, E239-43	55
1420	Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). <b>2014</b> , 164, 297-9	2

1419	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <b>2014</b> , 89, 743-50	13
1418	Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. <b>2014</b> , 20, 5641-51	28
1417	Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. <b>2014</b> , 92, 91-101	18
1416	TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. <b>2014</b> , 35, 663-71	23
1415	An old and simple solution for a new problem--more on clinical staging and evaluation of response in B-cell chronic lymphocytic leukaemia in the era of new therapies. <b>2014</b> , 165, 737-40	2
1414	Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?. <b>2014</b> , 28, 1055-71	1
1413	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. <b>2014</b> , 55, 2085-92	25
1412	High functional CD70 expression on $\beta$ -type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia. <b>2014</b> , 79, 415-22	5
1411	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <b>2014</b> , 167, 214-23	67
1410	Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. <b>2014</b> , 93, 29-33	19
1409	Chronic lymphocytic leukemia: a clinical review. <b>2014</b> , 312, 2265-76	100
1408	Weakness, fatigue, and an abnormal white blood cell count. <b>2014</b> , 312, 1051-2	
1407	Diagnostic moléculaire des hémopathies malignes. <b>2014</b> , 57-80	
1406	Association between polymorphism of GLI1 gene SNP rs2228226 and chronic lymphocytic leukemia in Chinese population. <b>2014</b> , 31, 294	5
1405	Added predictive value of omics data: specific issues related to validation illustrated by two case studies. <b>2014</b> , 14, 117	6
1404	Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases. <b>2014</b> , 93, 350-358	24
1403	Biclonal chronic lymphocytic leukemia presenting as skin lesion. <b>2014</b> , 36, 260-2	1
1402	Management of chronic lymphocytic leukemia. <b>2014</b> , 99, 965-72	28

1401	miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. <b>2014</b> , 55, 1544-50	10
1400	Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. <b>2014</b> , 55, 1774-80	11
1399	Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. <b>2014</b> , 55, 828-33	9
1398	U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. <b>2014</b> , 20, 3902-7	33
1397	Cytopathology in Oncology. <b>2014</b> ,	3
1396	Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. <b>2014</b> , 24, 821-8	15
1395	Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. <b>2014</b> , 55, 1768-73	15
1394	Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. <b>2014</b> , 150, 280-7	55
1393	Coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm. <b>2014</b> , 2014, 512928	1
1392	UGT1A1*28 polymorphism in chronic lymphocytic leukemia: the first investigation of the polymorphism in disease susceptibility and its specific cytogenetic abnormalities. <b>2014</b> , 132, 59-67	9
1391	Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting. <b>2014</b> , 5, e0027	1
1390	Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. <b>2014</b> , 2014, 423174	13
1389	B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. <b>2014</b> , 3, 29-38	6
1388	Emerging new anticancer biological therapies in 2013 (haematological malignancies). <b>2014</b> , 26, 363-70	5
1387	The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management. <b>2014</b> , 55, 1219-20	
1386	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. <b>2014</b> , 89, 74-82	18
1385	Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. <b>2014</b> , 36, 165-71	11
1384	The B-cell receptor pathway: a critical component of healthy and malignant immune biology. <b>2014</b> , 51, 206-18	21

1383	A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. <b>2014</b> , 20, 354-60	28
1382	Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. <b>2014</b> , 20, 881-4	23
1381	Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration. <b>2014</b> , 14, 73-9	3
1380	New horizons in the treatment of chronic lymphocytic leukemia. <b>2014</b> , 45, 122-131	6
1379	CD1d expression as a prognostic marker for chronic lymphocytic leukemia. <b>2014</b> , 55, 320-5	14
1378	The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. <b>2014</b> , 55, 1227-39	48
1377	Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway. <b>2014</b> , 38, 109-15	11
1376	Personalized medicine in CLL: current status and future perspectives. <b>2014</b> , 352, 4-14	21
1375	Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. <b>2014</b> , 32, 489-99	61
1374	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 2139-47	247
1373	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <b>2014</b> , 89, 480-6	86
1372	Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. <b>2014</b> , 192, 1620-9	42
1371	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <b>2014</b> , 370, 997-1007	1303
1370	CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. <b>2014</b> , 38, 435-42	22
1369	Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination. <b>2014</b> , 14, e131-5	4
1368	Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy. <b>2014</b> , 99, 782-5	2
1367	Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?. <b>2014</b> , 34, 277-82	58
1366	Ibrutinib for B cell malignancies. <b>2014</b> , 3, 4	56

1365	Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. <b>2014</b> , 93, 425-35	22
1364	Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling. <b>2014</b> , 7, 3	17
1363	Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. <b>2014</b> , 32, 193-207	13
1362	How the microenvironment wires the natural history of chronic lymphocytic leukemia. <b>2014</b> , 24, 43-8	67
1361	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 $\beta$ , for relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 3390-7	2.2 487
1360	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <b>2014</b> , 165, 629-39	44
1359	Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <b>2014</b> , 370, 1101-10	1048
1358	Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. <b>2014</b> , 89, 249-55	97
1357	Molecular Testing in Cancer. <b>2014</b> ,	1
1356	Long-term outcome of monoclonal (type 1) cryoglobulinemia. <b>2014</b> , 89, 156-61	38
1355	Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. <b>2014</b> , 192, 4518-24	19
1354	MicroRNA in Development and in the Progression of Cancer. <b>2014</b> ,	6
1353	TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia. <b>2014</b> , 31, 908	7
1352	Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia. <b>2014</b> , 28, 694-6	7
1351	Monoclonal B cell lymphocytosis and "in situ" lymphoma. <b>2014</b> , 24, 3-14	32
1350	PI3-kinase inhibitors in chronic lymphocytic leukemia. <b>2014</b> , 9, 33-43	21
1349	Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. <b>2014</b> , 38, 170-5	12
1348	Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. <b>2014</b> ,	5



1347	Bone Marrow and Stem Cell Transplantation. <b>2014</b> ,		1
1346	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <b>2014</b> , 49, 485-91		10
1345	Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice. <b>2014</b> , 14, 271-6		13
1344	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <b>2014</b> , 15, 48-58		372
1343	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. <b>2014</b> , 1, e74-84		76
1342	Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization. <b>2014</b> , 207, 316-25		12
1341	Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia. <b>2014</b> , 86, 91-7		1
1340	Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome. <b>2014</b> , 53, 788-97		13
1339	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. <b>2014</b> , 155, 160-75		113
1338	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , <b>2014</b> , 123, 3790-6	2.2	82
1337	CD84 is a survival receptor for CLL cells. <b>2014</b> , 33, 1006-16		27
1336	Neoplasms of Mature B, T and NK Cells. <b>2014</b> , 587-680		
1335	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <b>2014</b> , 99, 1421-32		42
1334	Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <b>2014</b> , 28, 642-8		48
1333	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <b>2014</b> , 371, 213-23		1154
1332	Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. <b>2014</b> , 28, 1365-8		18
1331	IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications. <b>2014</b> , 20, 323-30		24
1330	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. <b>2014</b> , 55, 571-82		6

1329	Analysis of activation-induced cytidine deaminase mRNA levels in patients with chronic lymphocytic leukemia with different cytogenetic status. <b>2014</b> , 55, 326-30	4
1328	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <b>2014</b> , 15, 1090-9	283
1327	Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. <b>2014</b> , 167, 224-32	22
1326	Les biomarqueurs moléculaires en oncologie. <b>2014</b> ,	
1325	A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). <b>2014</b> , 100, 290-5	5
1324	Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <b>2014</b> , 2014, 41-51	66
1323	How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation. <b>2014</b> , 31, 104	5
1322	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. <b>2014</b> , 28, 2005-15	37
1321	Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?. <b>2014</b> , 32, 869-72	32
1320	CD19 as a molecular target in CNS autoimmunity. <b>2014</b> , 128, 177-90	16
1319	Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. <b>2014</b> , 93, 1335-44	29
1318	Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. <b>2014</b> , 93, 1725-33	6
1317	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <b>2014</b> , 93, 1765-74	29
1316	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. <i>Blood</i> , <b>2014</b> , 123, 2378-88	2.2 64
1315	Autoimmune cytopenias in chronic lymphocytic leukemia. <b>2014</b> , 89, 1055-62	69
1314	Paving the road to MRD-guided treatment in CLL. <i>Blood</i> , <b>2014</b> , 123, 3683-4	2.2 6
1313	A role for oleoylethanolamide in chronic lymphocytic leukemia. <b>2014</b> , 28, 1381-7	17
1312	Applying consensus criteria to the evaluation of patients with suspected chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2014</b> , 6, 215-217	

1311	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. <b>2014</b> , 12, 52		31
1310	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. <i>Blood</i> , <b>2014</b> , 123, 3255-62	2.2	31
1309	Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. <b>2014</b> , 32, 2067-73		55
1308	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. <b>2014</b> , 32, 3039-47		96
1307	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <b>2014</b> , 120, 2000-5		27
1306	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. □ raport Grupy Roboczej PTHiT oraz PALG [CLL. <b>2014</b> , 45, 221-239		3
1305	Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. <b>2014</b> , 38, 484-9		7
1304	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. <b>2014</b> , 38, 34-41		23
1303	Conceptos básicos sobre síndromes mielo y linfoproliferativos. <b>2014</b> , 21, 17-25		
1302	Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. <b>2014</b> , 166, 360-8		19
1301	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <b>2014</b> , 38, 1165-72		10
1300	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <b>2014</b> , 42, 126-36.e1		20
1299	Transplantacje komórek krwiotwórczych w przewlekłej białaczce limfocytowej. <b>2014</b> , 45, 132-136		
1298	Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?. <i>Blood</i> , <b>2014</b> , 123, 1199-206	2.2	64
1297	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. <i>Blood</i> , <b>2014</b> , 123, 3727-32	2.2	109
1296	Anti-CD37 antibodies for chronic lymphocytic leukemia. <b>2014</b> , 14, 651-61		22
1295	NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <b>2014</b> , 55, 2785-92		40
1294	Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. <b>2014</b> , 38, 891-5		10

1293	PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). <b>2014</b> , 13, 1231-45		54
1292	Colocalization of BCL2-positive and -negative follicular lymphoma. <b>2014</b> , 28, 1368-70		
1291	Richter's syndrome [update on biology and management. <b>2014</b> , 2, 453-463		4
1290	Molecular Genetics of Chronic Lymphocytic Leukaemia. <b>2014</b> ,		
1289	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. <b>2014</b> , 99, 1095-100		74
1288	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <b>2014</b> , 99, 1285-91		1
1287	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 875-83	2.2	21
1286	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , <b>2014</b> , 123, 3247-54	2.2	352
1285	PKC- $\delta$ as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. <i>Blood</i> , <b>2014</b> , 124, 1481-91	2.2	38
1284	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , <b>2014</b> , 124, 3553-60	2.2	44
1283	SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. <i>Blood</i> , <b>2014</b> , 123, 1021-31	2.2	154
1282	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 1302-8	2.2	59
1281	How will B-cell-receptor-targeted therapies change future CLL therapy?. <i>Blood</i> , <b>2014</b> , 123, 1455-60	2.2	47
1280	Lymphocytosis and ibrutinib treatment of CLL. <i>Blood</i> , <b>2014</b> , 123, 1772-4	2.2	18
1279	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 124, 42-8	2.2	50
1278	Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. <i>Blood</i> , <b>2014</b> , 124, 2657-65	2.2	24
1277	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , <b>2014</b> , 124, 2190-5	2.2	88
1276	FDG/PET in CLL today. <i>Blood</i> , <b>2014</b> , 123, 2749-50	2.2	3

1275	Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). <i>Blood</i> , <b>2014</b> , 124, 3059-64	2.2	71
1274	Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. <i>Blood</i> , <b>2014</b> , 124, 2196-202	2.2	125
1273	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , <b>2014</b> , 124, 3841-9	2.2	158
1272	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. <i>Blood</i> , <b>2014</b> , 124, 2306-12	2.2	30
1271	New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients. <b>2014</b> , 12, 1371-5		3
1270	Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence. <b>2014</b> , 32, 169-77		12
1269	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <b>2014</b> , 99, e159-61		4
1268	Chronische lymphatische Leukämie beim alten Patienten. <b>2015</b> , 21, 486-495		
1267	Patient-reported outcomes in drug development for hematology. <b>2015</b> , 2015, 496-500		5
1266	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <b>2015</b> , 63, 216-27		11
1265	Lymphocytosis, lymphadenopathy: benign or malignant?. <b>2015</b> , 2015, 106-10		3
1264	Prognostic markers and standard management of chronic lymphocytic leukemia. <b>2015</b> , 2015, 368-77		24
1263	High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. <b>2015</b> , 90, 471-7		4
1262	Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. <b>2015</b> , 90, 487-92		22
1261	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <b>2015</b> , 54, 668-80		18
1260	Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. <b>2015</b> , 33, 15-22		17
1259	Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literature. <b>2015</b> , 3, 453-60		5
1258	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. <b>2015</b> , 100, 662-9		14

1257	Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2). <b>2015</b> ,		
1256	Chronic Lymphocytic Leukaemia and Other Chronic B-Cell Disorders. <b>2015</b> , 500-523		0
1255	Chronic Lymphocytic Leukemia. <b>2015</b> , 130-144		1
1254	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 125, 2336-43	2.2	127
1253	Initial treatment of CLL: integrating biology and functional status. <i>Blood</i> , <b>2015</b> , 126, 463-70	2.2	57
1252	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 125, 2915-22	2.2	92
1251	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , <b>2015</b> , 125, 3580-7	2.2	40
1250	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model. <i>Blood</i> , <b>2015</b> , 125, 4032-41	2.2	28
1249	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. <i>Blood</i> , <b>2015</b> , 125, 2779-85	2.2	63
1248	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood</i> , <b>2015</b> , 126, 842-50	2.2	111
1247	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. <i>Blood</i> , <b>2015</b> , 125, 3297-305	2.2	107
1246	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , <b>2015</b> , 125, 3024-31	2.2	212
1245	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 2686-94	2.2	194
1244	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. <i>Blood</i> , <b>2015</b> , 126, 2110-7	2.2	75
1243	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 1921-4	2.2	167
1242	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <b>2015</b> , 100, e501-4		18
1241	Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. <b>2015</b> , 100, 7-16		39
1240	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. <b>2015</b> , 13, 326-62		37

1239	The microenvironment in chronic lymphocytic leukemia: biology and therapeutic translation. <b>2015</b> , 56-71	
1238	Monoclonal B-cell lymphocytosis. <b>2015</b> , 37, 285-6	
1237	Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. <b>2015</b> , 10, 5	1
1236	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. <b>2015</b> , 8, 85	29
1235	Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. <b>2015</b> , 137, 2959-70	14
1234	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. <b>2015</b> , 100, 1495-507	69
1233	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <b>2015</b> , 170, 200-7	7
1232	MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia. <b>2015</b> , 282, 1939-52	4
1231	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. <b>2015</b> , 90, 967-9	2
1230	Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <b>2015</b> , 170, 694-703	16
1229	Clinicopathological and phenotypic features of chronic NK cell lymphocytosis identified among patients with asymptomatic lymphocytosis. <b>2015</b> , 37, 783-90	4
1228	Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population. <b>2015</b> , 86, 279-84	5
1227	Management of Chronic Lymphocytic Leukemia in the Elderly. <b>2015</b> , 22, 17-23	16
1226	Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. <b>2015</b> , 22, 7-16	3
1225	Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. <b>2015</b> , 95, 160-7	17
1224	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <b>2015</b> , 54, 818-26	27
1223	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <b>2015</b> , 121, 2883-91	47
1222	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <b>2015</b> , 90, 970-4	2



1221	Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo. <b>2015</b> , 80, 493-501	8
1220	Incidence of chromosomal anomalies detected by interphase FISH in chronic lymphoid leukemia. <b>2015</b> , 4, 133-141	2
1219	The expanding role of bendamustine in chronic lymphocytic leukemia. <b>2015</b> , 65	
1218	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. <b>2015</b> , 10, 4099-109	21
1217	Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. <b>2015</b> , 9, 13-22	4
1216	Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. <b>2015</b> , 19, 361-7	7
1215	The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma: a 25-year multicenter experience. <b>2015</b> , 10, e0119156	32
1214	Developing Molecular Signatures for Chronic Lymphocytic Leukemia. <b>2015</b> , 10, e0128990	8
1213	Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. <b>2015</b> , 10, e0130195	5
1212	High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis. <b>2015</b> , 10, e0140178	12
1211	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <b>2015</b> , 10, e0143073	23
1210	Isochromosome 17q in Chronic Lymphocytic Leukemia. <b>2015</b> , 2015, 489592	1
1209	. <b>2015</b> ,	2
1208	Management of chronic lymphocytic leukemia. <b>2015</b> , 164-75	20
1207	[Chronic lymphocytic leukemia: a paradigm shift What is the role of the biologist in this new world?]. <b>2015</b> , 73 Suppl 1, 19-21	
1206	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. <b>2015</b> ,	
1205	APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. <b>2015</b> , 21, 3934-45	28
1204	Rethinking clinical response and outcome assessment in a biologic age. <b>2015</b> , 17, 27	2



1203	Functional loss of <b>IB<math>\beta</math></b> leads to NF- <b>B</b> deregulation in aggressive chronic lymphocytic leukemia. <b>2015</b> , 212, 833-43	70
1202	Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. <b>2015</b> , 5, e303	25
1201	An unusual case of severe anaemia and lymphocytosis. <b>2015</b> , 350, h2673	2
1200	Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future. <b>2015</b> , 17, 31	3
1199	Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. <b>2015</b> , 15, 420-7	25
1198	Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. <b>2015</b> , 72, 933-42	6
1197	How best to manage patients with chronic lymphocytic leukemia with 17p deletion and/or TP53 mutation?. <b>2015</b> , 56, 587-93	13
1196	Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. <b>2015</b> , 36, 8317-24	16
1195	Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70. <b>2015</b> , 39, 773-8	6
1194	An automated approach to improve efficacy in detecting residual malignant cancer cell for facilitating prognostic assessment of leukemia: an initial study. <b>2015</b> ,	
1193	POEMS syndrome - A case report revealing a complex evolving diagnosis. <b>2015</b> , 3, 60-3	1
1192	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <b>2015</b> , 373, 2425-37	950
1191	Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. <b>2015</b> , 6, 8866	139
1190	BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. <b>2015</b> , 21, 5021-9	60
1189	Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. <b>2015</b> , 15 Suppl, S14-8	5
1188	Diagnostik maligner Lymphome. <b>2015</b> , 21, 897-904	
1187	AEGLE: A big bio-data analytics framework for integrated health-care services. <b>2015</b> ,	4
1186	Circulating classical CD14 <sup>++</sup> CD16 <sup>-</sup> monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163. <b>2015</b> , 34, 1269-78	9

1185	Mutacje TP53 w nowotworach hematologicznych. <b>2015</b> , 46, 327-338	
1184	Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphocytosis. <b>2015</b> , 54, 210-21	9
1183	Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression. <b>2015</b> , 8, 71-8	5
1182	Target antigen density governs the efficacy of anti-CD20-CD28-CD3 chimeric antigen receptor-modified effector CD8+ T cells. <b>2015</b> , 194, 911-20	150
1181	Multiple Targetoid Lesions in the Spleen: Sonographic Findings of Chronic Lymphocytic Leukemia and Their Relation to Effective Staging. <b>2015</b> , 31, 243-246	
1180	Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). <b>2015</b> , 90, 327-33	14
1179	Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. <b>2015</b> , 94, 249-56	8
1178	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <b>2015</b> , 16, 169-76	289
1177	SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. <b>2015</b> , 36, 4433-40	13
1176	Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10 <sup>9</sup> /L monoclonal lymphocytes better identifies subgroups with different outcomes. <b>2015</b> , 94, 627-32	6
1175	All-trans-retinoic Acid differentially regulates proliferation of normal and leukemic B cells from different subsets of chronic lymphocytic leukemia. <b>2015</b> , 67, 285-91	7
1174	Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. <b>2015</b> , 29, 1602-4	179
1173	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. <b>2015</b> , 54, 222-34	22
1172	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <b>2015</b> , 29, 1360-5	41
1171	Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program. <b>2015</b> , 15, e43-6	8
1170	The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6. <b>2015</b> , 359, 250-8	19
1169	Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL. <b>2015</b> , 169, 211-8	13
1168	Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2015</b> , 56, 2834-40	10

1167	Targeted therapy for chronic lymphocytic leukemia: current status and future directions. <b>2015</b> , 75, 143-55	4
1166	Clinical presentation, progression, and outcome of patients with clonal B-cell counts of less than 5 $\times 10^9/l$ , 5 to 10 $\times 10^9/l$ , and more than 10 $\times 10^9/l$ and chronic lymphocytic leukemia immunophenotype. <b>2015</b> , 143, 70-7	3
1165	TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. <b>2015</b> , 36, 3371-80	8
1164	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <b>2015</b> , 100, 511-6	34
1163	Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia. <b>2015</b> , 8, 38-42	0
1162	Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis. <b>2015</b> , 15, e55-60	3
1161	Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada. <b>2015</b> , 39, 429-34	6
1160	Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. <b>2015</b> , 90, 417-21	17
1159	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <b>2015</b> , 33, 423-31	25
1158	Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. <b>2015</b> , 64, 665-76	13
1157	Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. <i>Blood</i> , <b>2015</b> , 126, 454-62	2.2 131
1156	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. <b>2015</b> , 134, 208-14	15
1155	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <b>2015</b> , 15, 612-20.e1-5	19
1154	A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. <b>2015</b> , 56, 2826-33	125
1153	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <b>2015</b> , 21, 2115-2122	21
1152	CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia. <b>2015</b> , 55, 154-60	7
1151	Three-part differential of unlabeled leukocytes with a compact lens-free imaging flow cytometer. <b>2015</b> , 15, 1123-32	56
1150	Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. <i>Blood</i> , <b>2015</b> , 126, 766-78	2.2 33

1149	Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <b>2015</b> , 100, e237-9	17
1148	Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. <b>2015</b> , 56, 3065-70	15
1147	Emerging immunological drugs for chronic lymphocytic leukemia. <b>2015</b> , 20, 423-47	9
1146	CD14HLA-DR expression: A novel prognostic factor in chronic lymphocytic leukemia. <b>2015</b> , 9, 1167-1172	26
1145	Cutaneous manifestations in a patient with chronic lymphocytic leukemia involving the head, neck and distal extremities. <b>2015</b> , 9, 877-879	7
1144	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <b>2015</b> , 80, 1001-9	26
1143	Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową <b>2015</b> , 46, 35-41	
1142	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <b>2015</b> , 16, 704-15	189
1141	Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia. <b>2015</b> , 56, 113-9	18
1140	Przewlekła białaczka limfocytowa wysokiego ryzyka. <b>2015</b> , 46, 68-74	
1139	Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. <b>2015</b> , 90, 657-64	9
1138	Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. <b>2015</b> , 15, 385-91	22
1137	[Chronic lymphocytic leukemia : treatment concepts in transition]. <b>2015</b> , 56, 374-80	
1136	Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?. <b>2015</b> , 10, 59-64	10
1135	Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. <b>2015</b> , 101, 67-74	7
1134	Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients. <b>2015</b> , 36, 2863-8	5
1133	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. <b>2015</b> , 90, 446-60	175
1132	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. <b>2015</b> , 48, 849-54	23

1131	Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. <b>2015</b> , 29, 1524-9	81
1130	Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia. <b>2015</b> , 8, 20	15
1129	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <b>2015</b> , 385, 1873-83	263
1128	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Société Française de Greffe de Moelle et	8
1127	Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2015</b> , 165, 147-75	10
1126	A canadian perspective on the first-line treatment of chronic lymphocytic leukemia. <b>2015</b> , 15, 303-13	1
1125	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , <b>2015</b> , 125, 3236-45	90
1124	Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. <b>2015</b> , 11, 252-8	77
1123	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. <b>2015</b> , 170, 669-78	69
1122	A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders. <b>2015</b> , 56, 2619-24	9
1121	The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. <b>2015</b> , 34, 22-35	30
1120	Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. <b>2015</b> , 33, 1557-63	23
1119	The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. <b>2015</b> , 11, 51-9	18
1118	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , <b>2015</b> , 125, 2497-506	2.2 529
1117	Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. <b>2015</b> , 56, 2424-8	27
1116	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. <b>2015</b> , 6, 25-36	7
1115	The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. <b>2015</b> , 56, 3407-17	12
1114	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. <b>2015</b> , 39, 555-60	16

1113	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <b>2015</b> , 56, 3150-8	17
1112	An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. <b>2015</b> , 56, 2819-25	4
1111	Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <b>2015</b> , 21, 3160-9	46
1110	Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience. <b>2015</b> , 94, 1717-25	1
1109	Small cell B-cell lymphoma. <b>2015</b> , 21, 383-390	1
1108	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <b>2015</b> , 7, 303ra139	1071
1107	Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. <b>2015</b> , 5, e342	8
1106	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. <b>2015</b> , 71, 1121-7	2
1105	Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. <b>2015</b> , 56, 3336-42	29
1104	Venous thromboembolism in patients with chronic lymphocytic leukemia. <b>2015</b> , 136, 1082-6	15
1103	Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells. <b>2015</b> , 75, 4097-108	31
1102	Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. <b>2015</b> , 5, e273	17
1101	Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. <b>2015</b> , 94, 540-5	24
1100	Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. <b>2015</b> , 54, 424-37	13
1099	FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. <b>2015</b> , 21, 3586-90	90
1098	Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia. <b>2015</b> , 5, e353	6
1097	Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. <b>2015</b> , 56, 2373-8	15
1096	Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope. <b>2015</b> , 32, 877-86	3

1095	Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. <b>2015</b> , 15, 555	3
1094	Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. <b>2015</b> , 14, 114	18
1093	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <b>2015</b> , 39, 1066-70	25
1092	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. <b>2015</b> , 11, 1895-903	27
1091	Promising therapies for the treatment of chronic lymphocytic leukemia. <b>2015</b> , 24, 795-807	4
1090	Shifting paradigms in the treatment of chronic lymphocytic leukemia. <b>2015</b> , 11, 641-57	3
1089	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2015</b> , 26 Suppl 5, v78-84	269
1088	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <b>2015</b> , 100, 1180-8	53
1087	The clinical safety of ibrutinib in chronic lymphocytic leukemia. <b>2015</b> , 14, 1621-9	6
1086	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. <b>2015</b> , 16, 1370-9	91
1085	Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. <b>2015</b> , 8, 743-64	
1084	How I treat chronic lymphocytic leukemia in older patients. <b>2015</b> , 6, 333-40	5
1083	Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms. <b>2015</b> ,	5
1082	Obinutuzumab in chronic lymphocytic leukemia. <b>2015</b> , 11, 2503-13	1
1081	Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms. <b>2015</b> , 37, 486-94	16
1080	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <b>2015</b> , 56, 1643-50	93
1079	Emerging therapies for refractory chronic lymphocytic leukemia. <b>2015</b> , 56, 285-92	2
1078	De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. <b>2015</b> , 15, 493-9	1



1077	Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2015</b> , 56, 645-9	23
1076	Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. <b>2015</b> , 15, 9-15	5
1075	Stereospecific ligands and their complexes. XXII. Synthesis and antitumor activity of palladium(II) complexes with some esters of (S,S)-ethylenediamine-N,N'-di-(2,2'-di(4-hydroxy-benzyl))-acetic acid. <b>2015</b> , 143, 111-6	10
1074	Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. <b>2015</b> , 100, 370-6	43
1073	A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. <b>2015</b> , 41, 77-93	11
1072	Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). <b>2015</b> , 90, 204-7	29
1071	Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. <b>2015</b> , 15, 314-22	12
1070	Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma. <b>2015</b> , 139, 602-7	11
1069	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. <b>2015</b> , 56, 311-4	12
1068	Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes. <b>2015</b> , 15, 73-83	17
1067	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. <b>2015</b> , 56, 1626-35	
1066	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <b>2015</b> , 29, 598-605	92
1065	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. <b>2015</b> , 21, 281-7	16
1064	Management of Hematological Cancer in Older People. <b>2015</b> ,	
1063	Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. <b>2015</b> , 168, 350-60	9
1062	Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. <b>2015</b> , 94, 593-601	5
1061	Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. <b>2015</b> , 56, 1585-92	15
1060	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. <b>2015</b> , 56, 711-5	13



1059	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. <b>2015</b> , 33, 540-9	1155
1058	Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. <b>2015</b> , 56, 694-702	5
1057	Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2015</b> , 56, 915-20	26
1056	Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. <b>2015</b> , 54, 97-102	22
1055	Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <b>2015</b> , 29, 329-36	220
1054	A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia. <b>2015</b> , 56, 1831-8	8
1053	Richter's transformation presenting as splenic rupture after 6 years of complete remission of chronic lymphocytic leukaemia. <b>2016</b> , 2016,	1
1052	Chronic Lymphocytic Leukemia, the Prototypic Chronic Leukemia for Flow Cytometric Analysis. <b>2016</b> , 226-234	
1051	Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia. <b>2016</b> ,	78
1050	11. Chronic lymphocytic leukemia. <b>2016</b> , 205-228	
1049	Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia. <b>2016</b> , 9, 797-805	6
1048	The Danish National Chronic Lymphocytic Leukemia Registry. <b>2016</b> , 8, 561-565	25
1047	Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. <b>2016</b> , 7, 13551-62	18
1046	Practical approach to management of chronic lymphocytic leukemia. <b>2016</b> , 12, 448-56	5
1045	Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals. <b>2016</b> , 04,	
1044	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. <b>2016</b> , 35, e387-98	17
1043	[New insights in the treatment of chronic lymphocytic leukemia and role of the biologist in the monitoring of the treatments]. <b>2016</b> , 74, 176-83	
1042	Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia. <b>2016</b> , 32, 1213-1217	

1041	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. <b>2016</b> , 7, 80916-80924	23
1040	Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia. <b>2016</b> , 7, 86469-86479	18
1039	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <b>2016</b> , 12, 421-7	8
1038	A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia. <b>2016</b> , 23, 42-51	19
1037	Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. <b>2016</b> , 11, e0167641	20
1036	Next-generation sequencing: advances and applications in cancer diagnosis. <b>2016</b> , 9, 7355-7365	103
1035	Evaluation of Periodontal Parameters in Patients with Early Stage Chronic Lymphocytic Leukemia. <b>2016</b> , 50, 23-33	2
1034	To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. <b>2016</b> , 7, 22324-38	14
1033	Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. <b>2016</b> , 175, 55-65	11
1032	Immunostimulation by cytosine-phosphate-guanine oligodeoxynucleotides in combination with IL-2 can improve the success rate of karyotype analysis in chronic lymphocytic leukaemia. <b>2016</b> , 73, 110-114	1
1031	LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations. <b>2016</b> , 97, 175-82	12
1030	Incidence rates of chronic lymphocytic leukemia in US states are associated with residential radon levels. <b>2016</b> , 12, 165-74	19
1029	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <b>2016</b> , 34, 84-92	21
1028	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). <b>2016</b> , 91, 308-12	9
1027	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <b>2016</b> , 91, 687-91	11
1026	Chronic lymphocytic leukaemia. <b>2016</b> , 104, 169-82	85
1025	Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL. <b>2016</b> , 6, e440	3
1024	The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. <b>2016</b> , 47, 166-71	9

1023	Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. <b>2016</b> , 122, 2505-11		27
1022	Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. <b>2016</b> , 172, 371-383		15
1021	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. <b>2016</b> , 97, 253-60		18
1020	Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry. <b>2016</b> , 60, 372-384		18
1019	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. <b>2016</b> , 9, 88		26
1018	Targeting BTK through microRNA in chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 128, 3101-3112	2.2	25
1017	Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules. <b>2016</b> , 4, 2050313X16683624		5
1016	SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. <b>2016</b> , 101, 1553-1562		10
1015	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <b>2016</b> , 101, e254-8		32
1014	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , <b>2016</b> , 128, 2899-2908	2.2	52
1013	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , <b>2016</b> , 128, 2527-2532	2.2	115
1012	Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. <b>2016</b> , 64, 137-145		14
1011	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. <b>2016</b> , 101, e369-73		11
1010	Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood</i> , <b>2016</b> , 128, 2770-2773		85
1009	Evolution of multiple cell clones over a 29-year period of a CLL patient. <b>2016</b> , 7, 13765		21
1008	Advances in the treatment of chronic lymphocytic leukaemia. <b>2016</b> , 147, 447-454		
1007	Sequencing of chronic lymphocytic leukemia therapies. <b>2016</b> , 2016, 128-136		11
1006	Prognostication of chronic lymphocytic leukemia in the era of new agents. <b>2016</b> , 2016, 149-155		24

1005	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , <b>2016</b> , 128, 2199-2205	2.2	135
1004	[Flow-cytometric immunophenotyping in clinical diagnostics]. <b>2016</b> , 141, 1569-1574		
1003	National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data. <b>2016</b> , 5, 3588-3595		14
1002	Ophthalmic manifestations of leukemia. <b>2016</b> , 27, 545-551		50
1001	Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups. <b>2016</b> , 6, e389		4
1000	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <b>2016</b> , 101, 959-67		41
999	Protocolo de práctica asistencial de las linfocitosis crónicas. <b>2016</b> , 12, 1245-1248		
998	Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report. <b>2016</b> , 10, 123		7
997	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. <b>2016</b> , 101, 1573-1580		88
996	Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. <b>2016</b> , 5, 25355		72
995	The clinical implications of gene mutations in chronic lymphocytic leukaemia. <b>2016</b> , 114, 849-54		25
994	Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. <b>2016</b> , 47, 78-83		13
993	BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients. <b>2016</b> , 11, 3240-3246		11
992	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <b>2016</b> , 17, 768-778		536
991	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. <b>2016</b> , 76, 2540-51		21
990	Concept Elicitation Within Patient-Powered Research Networks: A Feasibility Study in Chronic Lymphocytic Leukemia. <b>2016</b> , 19, 42-52		13
989	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. <b>2016</b> , 57, 2409-16		12
988	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. <b>2016</b> , 17, 928-942		416

987	Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. <b>2016</b> , 30, 2232-2234	18
986	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <b>2016</b> , 57, 2685-8	14
985	An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases. <b>2016</b> , 35, 5328-5336	7
984	Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. <b>2016</b> , 30, 1301-10	32
983	A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells. <b>2016</b> , 15, 971-84	6
982	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. <b>2016</b> , 43, 300-10	16
981	What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges. <b>2016</b> , 43, 201-8	13
980	B Cell Anergy Modulated by TLR1/2 and the miR-17~92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4. <b>2016</b> , 196, 4410-7	20
979	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. <b>2016</b> , 57, 1291-9	16
978	Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. <b>2016</b> , 35, 5663-5673	40
977	Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable. <b>2016</b> , 38, 889-904.e14	11
976	Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. <b>2016</b> , 11, 335-43	17
975	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. <b>2016</b> , 37, 11947-11957	20
974	Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation. <b>2016</b> , 57, 985-6	
973	The parallel application of karyotype interphase and metaphase FISH after DSP-30/IL-2 stimulation is necessary for the investigation of chronic lymphocytic leukemia. <b>2016</b> , 21, 526-35	1
972	Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. <b>2016</b> , 95, 853-61	3
971	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <b>2016</b> , 3, e128-38	28
970	Clinical challenge: An orbital Hickam's dictum. <b>2016</b> , 61, 799-805	4

969	Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2. <b>2016</b> , 11, 449-55		14
968	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <b>2016</b> , 30, 2011-2018		33
967	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <b>2016</b> , 60, 154-65		16
966	Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment. <b>2016</b> , 9, 525-536		24
965	Idelalisib for treatment of B-cell malignancies. <b>2016</b> , 73, 547-55		14
964	An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. <b>2016</b> , 17, 779-790		379
963	Analysis of prognosis in CLL: collaboration makes the difference. <b>2016</b> , 17, 691-692		
962	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 127, 79-86	2.2	59
961	HIF-1 $\beta$ regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. <i>Blood</i> , <b>2016</b> , 127, 1987-97	2.2	41
960	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , <b>2016</b> , 127, 411-9	2.2	195
959	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 127, 303-9	2.2	347
958	Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <i>Blood</i> , <b>2016</b> , 127, 1752-60	2.2	53
957	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , <b>2016</b> , 127, 1007-16	2.2	110
956	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , <b>2016</b> , 127, 2411-5	2.2	113
955	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , <b>2016</b> , 127, 3215-24	2.2	181
954	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. <i>Blood</i> , <b>2016</b> , 128, 395-404	2.2	92
953	Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 127, 2356-8	2.2	19
952	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , <b>2016</b> , 128, 195-203	2.2	222

951	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. <i>Blood</i> , <b>2016</b> , 128, 816-26	2.2	39
950	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <b>2016</b> , 101, 1002-9		30
949	Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial. <b>2016</b> , 101, e192-5		22
948	Posttranscriptional Upregulation of p53 by Reactive Oxygen Species in Chronic Lymphocytic Leukemia. <b>2016</b> , 76, 6311-6319		2
947	TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia. <b>2016</b> , 50, 72-77		12
946	[Advances in the treatment of chronic lymphocytic leukaemia]. <b>2016</b> , 147, 447-454		
945	Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia. <b>2016</b> , 50, 63-71		6
944	A case of SRSF2 mutation in chronic lymphocytic leukemia. <b>2016</b> , 6, 11-4		1
943	ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. <b>2016</b> , 27, 2149-2160		13
942	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2016</b> , 57, 2212-5		10
941	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <b>2016</b> , 22, 2117-2125		70
940	Current strategies to create tailored and risk-adapted therapies for CLL patients. <b>2016</b> , 29, 111-121		3
939	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. <b>2016</b> , 714-726		
938	New treatment approaches in CLL: Challenges and opportunities in the elderly. <b>2016</b> , 7, 375-82		12
937	Lenalidomide in chronic lymphocytic leukemia. <b>2016</b> , 4, 971-980		
936	Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. <b>2016</b> , 55, 1115-1120		13
935	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <b>2016</b> , 91, 1090-1095		43
934	Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada. <b>2016</b> , 55, 16-24		8



933	Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. <b>2016</b> , 175, 641-651	18
932	Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?. <b>2016</b> , 279, 347-57	34
931	Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population-based study. <b>2016</b> , 5, 971-9	11
930	Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. <b>2016</b> , 172, 819-23	6
929	CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. <b>2016</b> , 172, 48-55	16
928	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <b>2016</b> , 96, 36-45	6
927	Breed Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs. <b>2016</b> , 30, 215-22	20
926	Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <b>2016</b> , 101, e295-8	54
925	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. <b>2016</b> , 34, 3758-3765	111
924	Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. <b>2016</b> , 30, 2419-2422	22
923	Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. <b>2016</b> , 95, 1989-1997	14
922	Role of microRNAs in regulation of the TNF/TNFR gene superfamily in chronic lymphocytic leukemia. <b>2016</b> , 49, 1307-1310	12
921	Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia. <b>2016</b> , 37, 13617-13626	9
920	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. <b>2016</b> , 197, 2532-40	78
919	Present and future of personalized medicine in CLL. <b>2016</b> , 29, 100-110	8
918	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <b>2016</b> , 101, 77-85	37
917	Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?. <b>2016</b> , 16 Suppl, S74-81	17
916	Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. <b>2016</b> , 57, 2417-20	3



915	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , <b>2016</b> , 128, 2489-2496	2.2	235
914	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <b>2016</b> , 17, 1409-1418		233
913	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. <b>2016</b> , 38, 346-357		17
912	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <b>2016</b> , 3, e407-14		15
911	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. <b>2016</b> , 113, 395-408		59
910	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , <b>2016</b> , 127, 3015-25	2.2	55
909	Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. <b>2016</b> , 5, e1226720		75
908	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. <i>Blood</i> , <b>2016</b> , 127, 449-57	2.2	42
907	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <b>2016</b> , 66, 443-459		504
906	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). <b>2016</b> , 172, 52-60		4
905	Isolation of Human Genomic DNA Sequences with Expanded Nucleobase Selectivity. <b>2016</b> , 138, 9910-8		18
904	A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. <b>2016</b> , 91, 1020-5		11
903	Secondary immunodeficiency in lymphoproliferative malignancies. <b>2016</b> , 34, 121-32		43
902	Night shift work and chronic lymphocytic leukemia in the MCC-Spain case-control study. <b>2016</b> , 139, 1994-2000		13
901	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. <b>2016</b> , 3, e317-29		35
900	Massive and parallel expression profiling using microarrayed single-cell sequencing. <b>2016</b> , 7, 13182		33
899	Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. <b>2016</b> , 6, e499		29
898	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <b>2016</b> , 175, 892-903		37

897	Clinical Morphological Studies of Myelofibrosis with Different Types of Bone Marrow Involvement in Patients with Chronic Lymphocytic Leukemia. <b>2016</b> , 161, 408-11	1
896	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. <b>2016</b> , 8, 106	34
895	Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis. <b>2016</b> ,	4
894	Proliferation centers in bone marrows involved by chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic analysis. <b>2016</b> , 25, 15-19	3
893	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. <b>2016</b> , 9, 1177-1187	2
892	A comparative protein profiling of lymphocytes from blood of patients with chronic lymphoid leukemia by high-resolution mass-spectrometry in search of new markers for heterogeneity and disease prognosis. <b>2016</b> , 71, 1242-1250	1
891	Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. <b>2016</b> , 17, 456	1
890	Individualisiertes Vorgehen zur Optimierung des Behandlungserfolges. <b>2016</b> , 19, 40-48	
889	A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. <b>2016</b> , 91, 900-6	19
888	$\kappa$ -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. <b>2016</b> , 122, 565-73	14
887	Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. <b>2016</b> , 5, 27-35	15
886	[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. <b>2016</b> , 59, 444-53	0
885	Neue Therapiekonzepte bei der chronisch-lymphatischen Leukämie. <b>2016</b> , 22, 283-294	3
884	Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears. <b>2016</b> , 64, 495-501	1
883	Two rare diagnoses during chronic lymphocytic leukaemia follow-up: Kaposi's sarcoma and Merkel cell carcinoma. <b>2016</b> , 61, 60-3	4
882	Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2016</b> , 12, 2077-94	9
881	Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. <b>2016</b> , 95, 1473-82	6
880	Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?. <b>2016</b> , 9, 679-93	2

879	A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. <b>2016</b> , 7, e2249	20
878	Transformation in Low-grade B-cell Neoplasms. <b>2016</b> , 9, 79-92	12
877	The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. <b>2016</b> , 7, 69-84	21
876	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. <b>2016</b> , 9, 28	32
875	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. <b>2016</b> , 4, 698-707	11
874	Role of precision medicine in the treatment of chronic lymphocytic leukaemia. <b>2016</b> , 1, 145-154	
873	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <b>2016</b> , 5, e1150399	55
872	Measurement of lymphocyte aggregation by flow cytometry-physiological implications in chronic lymphocytic leukemia. <b>2016</b> , 90, 257-66	5
871	Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib. <b>2016</b> , 22, 62-6	4
870	The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with . <b>2016</b> , 173, 127-36	12
869	Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. <b>2016</b> , 96, 229-35	11
868	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. <b>2016</b> , 57, 2037-46	16
867	Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. <b>2016</b> , 103, 86-94	24
866	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. <b>2016</b> , 34, 1112-21	391
865	Targeted therapies for CLL: Practical issues with the changing treatment paradigm. <b>2016</b> , 30, 233-44	57
864	Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. <b>2016</b> , 51, 793-8	21
863	Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. <b>2016</b> , 9, 245-54	1
862	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. <b>2016</b> , 30, 1440-3	21

861	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <b>2016</b> , 30, 929-36	142
860	Association of various risk factors with chronic lymphocytic leukemia and its cytogenetic characteristics. <b>2016</b> , 71, 317-329	13
859	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <b>2016</b> , 17, 200-211	314
858	Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise. <b>2016</b> , 16, 63-9	5
857	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <b>2016</b> , 374, 323-32	621
856	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <b>2016</b> , 374, 311-22	1164
855	Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems. <b>2016</b> , 60, 342-51	12
854	Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials. <b>2016</b> , 57, 2047-57	13
853	Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada. <b>2016</b> , 34, 77-90	7
852	C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation. <b>2016</b> , 21, 343-50	2
851	Ibrutinib for treatment of chronic lymphocytic leukemia. <b>2016</b> , 73, 367-75	9
850	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. <b>2016</b> , 17, 1077-89	11
849	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. <b>2016</b> , 57, 1585-91	9
848	Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. <b>2016</b> , 44, 53-60	18
847	Chronic lymphocytic leukemia (CLL)-Then and now. <b>2016</b> , 91, 330-40	83
846	Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. <b>2016</b> , 95, 863-70	9
845	Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. <b>2016</b> , 183, 90-101	27
844	Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). <b>2016</b> , 96, 9-18	24

843	Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. <b>2016</b> , 6, e404	12
842	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. <b>2016</b> , 8, 787-98	6
841	Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature. <b>2016</b> , 4, 682-694	11
840	Expression of IL-1 and IL-6 and their natural regulators in leukocytes of B-cell chronic lymphocytic leukaemia patients. <b>2016</b> , 61, 187-192	4
839	State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. <b>2016</b> , 39, 25-32	23
838	The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. <b>2016</b> , 43, 260-4	32
837	Prognostic factors and risk stratification in chronic lymphocytic leukemia. <b>2016</b> , 43, 233-40	48
836	Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to composite diffuse large b-cell lymphoma and hodgkin lymphoma: a case report and review of literature. <b>2018</b> , 14, 69-72	1
835	Targeting epidermal growth factor receptors inhibition in non-small-cell lung cancer: a computational approach. <b>2018</b> , 44, 1478-1488	6
834	Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis. <b>2018</b> , 35, 144	5
833	Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?. <b>2018</b> , 73, 16-20	8
832	CLL Next Questions. <b>2018</b> , 18, S123-S124	
831	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <b>2018</b> , 16, 172	17
830	Cytotoxicity and Apoptosis Induction by Coumarins in CLL. <b>2018</b> ,	
829	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. <b>2018</b> , 18, S19-S20	
828	B-cell chronic lymphocytic leukaemia in an African lion ( <i>Panthera leo</i> ). <b>2018</b> , 63, 433-437	1
827	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <b>2018</b> , 2, 1705-1718	9
826	CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM. <b>2018</b> , 2, 1869-1881	8

825	Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. <b>2018</b> , 2, 3566-3571	16
824	CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. <b>2018</b> , 40, 533-539	12
823	Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. <b>2018</b> , 97, 1649-1661	8
822	Paraneoplastische, Pyoderma gangraenosum-artige Ulzeration bei T-Zell-Leukämie mit großen granulösen Zellen (T-Zell-LGL-Leukämie). <b>2018</b> , 16, 342-344	
821	A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. <b>2018</b> , 59, 2888-2895	24
820	The prognostic role of HBV infection in chronic lymphocytic leukemia. <b>2018</b> , 144, 1309-1315	3
819	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. <b>2018</b> , 18, 508-518.e14	10
818	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. <b>2018</b> , 2018, 9506979	15
817	Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. <b>2018</b> , 103, 1881-1888	13
816	Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. <b>2018</b> , 2018, 2426712	19
815	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <b>2018</b> , 18, 737-742	1
814	Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. <b>2018</b> , 18, e421-e426	6
813	Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <b>2018</b> , 101, 399-406	5
812	Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. <b>2018</b> , 97, 2153-2161	4
811	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <b>2018</b> , 18, 648-657.e15	45
810	Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales. <b>2018</b> , 97, 1859-1868	7
809	Immunophenotypic profile and clinical outcome of monoclonal B-cell lymphocytosis in kidney transplantation. <b>2018</b> , 32, e13338	5
808	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <b>2018</b> , 101, 703	5

807	Small Molecules in Hematology. <b>2018</b> ,		4
806	Ibrutinib. <b>2018</b> , 212, 133-168		19
805	Chronic Lymphocytic Leukemia. <b>2018</b> , 1244-1264		2
804	Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. <b>2018</b> , 11, 613-624		14
803	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <b>2018</b> , 103, 1889-1898		13
802	Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. <b>2018</b> , 182, 344-359		20
801	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , <b>2018</b> , 132, 892-902	2.2	64
800	A History of the Chronic Leukemias. <b>2018</b> , 3-8		
799	Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses. <b>2018</b> , 183, 47-59		2
798	A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion. <b>2018</b> , 97, 1663-1669		6
797	Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia. <b>2018</b> , 70, 25-33		2
796	Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3). <b>2018</b> , 11, 3		3
795	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. <b>2018</b> , 93, 651-664		18
794	Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. <b>2018</b> , 103, 931-938		20
793	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <b>2018</b> , 32, 1778-1786		20
792	How and when I do allogeneic transplant in CLL. <i>Blood</i> , <b>2018</b> , 132, 31-39	2.2	34
791	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2018</b> , 132, 1568-1572	2.2	81
790	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <b>2018</b> , 9, 13023-13035		45



789	Duvelisib, an oral dual PI3K- $\gamma$ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. <b>2018</b> , 93, 1318-1326	33
788	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. <b>2018</b> , 24, 6185-6194	106
787	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <b>2018</b> , 38, 31	4
786	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <b>2018</b> , 201, 1967-1974	18
785	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <b>2018</b> , 93, 1394-1401	37
784	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. <b>2018</b> , 19, 1215-1228	70
783	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <b>2018</b> , 6, 1150-1160	40
782	Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. <b>2018</b> , 72, 113-119	4
781	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <b>2018</b> , 18, 803-813.e7	27
780	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. <b>2018</b> , 32, 125-133	2
779	Molecular Basis of Lymphoid and Myeloid Diseases. <b>2018</b> , 299-328	1
778	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <b>2018</b> , 182, 504-512	32
777	Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. <b>2018</b> , 37, 5520-5533	27
776	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <b>2018</b> , 24, 4371-4379	90
775	Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. <b>2018</b> , 36, 656-662	1
774	Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells. <b>2018</b> , 70, 79-86	9
773	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <b>2018</b> , 26, 1896-1905	46
772	Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia. <b>2018</b> , 13, e0191205	3



771	B-Cell Lymphocytosis. <b>2018</b> , 329-381	
770	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <b>2018</b> , 103, 1502-1510	82
769	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <b>2018</b> , 103, 1511-1517	91
768	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. <b>2019</b> , 60, 658-667	13
767	A phase 2 study of ofatumumab (Arzerra) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL). <b>2019</b> , 60, 92-100	5
766	Study of microRNA Profile as a Molecular Biomarker in Egyptian Chronic Lymphocytic Leukemia. <b>2019</b> , 35, 89-99	2
765	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. <b>2019</b> , 33, 390-402	30
764	Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study. <b>2019</b> , 185, 148-150	2
763	Diagnosis and classification of lymphoma: Impact of technical advances. <b>2019</b> , 56, 30-36	12
762	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <b>2019</b> , 185, 193-197	16
761	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. <b>2019</b> , 104, 147-154	7
760	Methods and role of minimal residual disease after stem cell transplantation. <b>2019</b> , 54, 681-690	3
759	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. <b>2019</b> , 185, 347-350	3
758	Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. <b>2019</b> , 60, 3204-3213	7
757	Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years. <b>2019</b> , 85, 106218	4
756	Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. <b>2019</b> , 19, 809	4
755	Distribution of Some Functional Molecules on T-Lymphocytes in Chronic Lymphoblastic Leukemia. <b>2019</b> , 13, 198-206	
754	Neue Therapiemöglichkeiten für Patienten mit CLL. <b>2019</b> , 22, 18-24	

753	Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. <b>2019</b> , 142, 58-67		11
752	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , <b>2019</b> , 134, 851-859	2.2	151
751	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <b>2019</b> , 60, 3461-3469		9
750	Neue Therapiemöglichkeiten für Patienten mit CLL. <b>2019</b> , 22, 47-55		
749	Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis. <b>2019</b> , 10, 199-208		10
748	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <b>2019</b> , 6, e470-e479		14
747	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <b>2019</b> , 6, e419-e428		41
746	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <b>2019</b> , 37, 2722-2729		120
745	A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. <b>2019</b> , 103, 335-341		4
744	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 134, 1132-1143	2.2	46
743	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <b>2019</b> , 381, 432-443		322
742	Elevated expression determines a worse prognosis in chronic lymphocytic leukemia and interferes with p53 function. <b>2019</b> , 33, 10477-10489		2
741	SYNTHESIS AND ANTICANCER SCREENING OF TRIAZINE ANALOGUES. <b>2019</b> , 114-121		2
740	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <b>2019</b> , 6, e366-e374		36
739	Chronic lymphocytic leukaemia: from genetics to treatment. <b>2019</b> , 16, 684-701		85
738	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <b>2019</b> , 11,		7
737	Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. <b>2019</b> , 94, 1325-1334		20
736	Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. <b>2019</b> , 11,		

735	Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia. <b>2019</b> , 11,	4
734	PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. <b>2019</b> , 14, 405-410	6
733	Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. <b>2019</b> , 64, 155-162	
732	Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia. <b>2019</b> , 55,	3
731	Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia. <b>2019</b> , 12, 183-190	
730	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <b>2019</b> , 94, 1353-1363	152
729	Chronic Lymphocytic Leukemia. <b>2019</b> , 332-341	
728	Cytogenetic landscape in 1012 newly diagnosed chronic lymphocytic leukemia. <b>2019</b> , 103, 607-613	3
727	Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia. <b>2019</b> , 12, 4	7
726	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. <b>2019</b> , 7, 227	38
725	Rapid clinical progression of B-cell chronic lymphocytic leukemia in a horse. <b>2019</b> , 255, 716-721	2
724	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 134, 1811-1820	2.2 50
723	[Chronic lymphocytic leukemia]. <b>2019</b> , 48, 807-815	6
722	Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. <b>2019</b> , 53, 839-848	1
721	Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. <b>2019</b> , 33, 1650-1662	8
720	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <b>2019</b> , 6, e100-e109	48
719	Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <b>2019</b> , 33, 1801-1805	4
718	Focus on pre-processing step to ensure the clinical transferability of Raman data acquired on lymphocytes in different experimental and instrumental conditions. <b>2019</b> , 103, 102931	5

717	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <b>2019</b> , 121, 150-156	17
716	Bacterial Colonization in Patients with Chronic Lymphocytic Leukemia and Factors Associated with Infections and Colonization. <b>2019</b> , 8,	7
715	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). <b>2019</b> , 94, 1002-1006	3
714	The Clinical Presentation of CLL. <b>2019</b> , 39-50	0
713	Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia. <b>2019</b> , 187, 82-92	2
712	Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients. <b>2019</b> , 11, 5021-5031	2
711	Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. <b>2019</b> , 186, 845-854	12
710	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. <b>2019</b> , 5,	42
709	Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis. <b>2019</b> , 8,	3
708	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <b>2019</b> , 380, 2095-2103	256
707	Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia. <b>2019</b> , 12, 282	1
706	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <b>2019</b> , 380, 2225-2236	368
705	SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. <b>2019</b> , 19, 321-325	1
704	A review of chimeric antigen receptor T-cells in lymphoma. <b>2019</b> , 12, 551-561	9
703	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. <b>2019</b> , 21-35	2
702	Monoclonal B-cell lymphocytosis. <b>2019</b> , 32, 229-238	9
701	Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report. <b>2019</b> , 39, 2805-2810	2
700	Chronic Lymphocytic Leukemia: Who, How, and Where?. <b>2019</b> , 3-17	2

699	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <b>2019</b> , 104, 2053-2060		39
698	Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. <b>2019</b> , 33, 2531-2535		14
697	Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. <b>2019</b> , 60, 2931-2938		4
696	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy. <i>Blood</i> , <b>2019</b> , 134, 44-58	2.2	69
695	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. <b>2019</b> , 39, 2591-2598		
694	Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. <b>2019</b> , 104, 2429-2442		7
693	"Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia. <b>2019</b> , 95, 521-533		8
692	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <b>2019</b> , 37, 1391-1402		109
691	Autoimmune Cytopenia in Chronic Lymphocytic Leukemia. <b>2019</b> , 123-136		
690	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <b>2019</b> , 36, 93		2
689	Simultaneous Analysis of Phenotype and Cytogenetics Using Imaging Flow Cytometry: Time to Teach Old Dogs New Tricks. <b>2019</b> , 95, 943-945		0
688	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. <b>2019</b> , 69-77		
687	Analysis of basal chromosome instability in patients with chronic lymphocytic leukaemia. <b>2019</b> , 34, 245-252		2
686	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , <b>2019</b> , 134, 111-122	2.2	94
685	Chronic Lymphocytic Leukemia. <b>2019</b> ,		
684	Targeting BTK in CLL: Beyond Ibrutinib. <b>2019</b> , 14, 197-205		65
683	Molecular Diagnostics in Non-Hodgkin Lymphoma. <b>2019</b> , 103-127		
682	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. <b>2019</b> , 19, 678-685.e4		12

- 681 Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. **2019**, 96, 94-103 8
- 680 The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia. **2019**, 12, 97-104 5
- 679 Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. *Blood*, **2019**, 133, 2031-2042 123
- 678 Glomerular Diseases Associated with Malignancies. **2019**, 691-734
- 677 Allogeneic Transplantation after Myeloablative Rituximab/BEAM + Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. **2019**, 25, 1347-1354 0
- 676 High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. **2019**, 104, 2249-2257 2
- 675 A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. **2019**, 109, 657-664 19
- 674 Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial. **2019**, 8, 1540-1550 8
- 673 Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. *Blood*, **2019**, 133, 2765-2775 2.2 42
- 672 Red blood cell utilization and transfusion triggers in patients diagnosed with chronic lymphocytic leukaemia in Iceland 2003-2016. **2019**, 114, 495-504
- 671 Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. *Blood*, **2019**, 133, 2651-2663 2.2 10
- 670 Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. **2019**, 110, 1686-1694 30
- 669 Le urgenze ematologiche. **2019**, 1-100
- 668 Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience. **2019**, 98, 1477-1483 3
- 667 Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan. **2019**, 12, 202 7
- 666 Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. **2019**, 104, 2258-2264 16
- 665 Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine. **2019**, 60, 1266-1274 1
- 664 Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. **2019**, 79, 17-21 4

663	Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. <b>2019</b> , 109, 196-203		6
662	Parsaclisib, a potent and highly selective PI3K $\gamma$ inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , <b>2019</b> , 133, 1742-1752	2.2	47
661	Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. <b>2019</b> , 30, 542-550		4
660	Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. <b>2019</b> , 37, 185-192		7
659	New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia. <b>2019</b> ,		
658	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <b>2019</b> , 3, 1553-1562		101
657	Obstructive sleep apnoea in a patient with chronic lymphocytic leukaemia. <b>2019</b> , 12,		1
656	IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. <b>2019</b> , 3, 2188-2198		14
655	Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. <b>2019</b> , 3, 447-460		24
654	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <b>2019</b> , 3, 1799-1807		61
653	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <b>2019</b> , 3, 1167-1174		16
652	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <b>2019</b> , 3, 1568-1573		18
651	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <b>2019</b> , 3, 3062-3069		37
650	Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2019</b> , 59, 179-186		1
649	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naïve and relapsed CLL. <b>2019</b> , 3, 1533-1539		5
648	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. <b>2019</b> , 12, 114		3
647	Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?. <b>2019</b> , 19, 1086		1
646	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <b>2019</b> , 17, 173		3



645	Cross-talk between Myc and p53 in B-cell lymphomas. <b>2019</b> , 5, 139-154	10
644	Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia. <b>2019</b> , 132, 525-533	1
643	Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups. <b>2019</b> , 20,	4
642	Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. <b>2019</b> , 5, 1-19	10
641	Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. <b>2019</b> , 24, 1237-1245	2
640	Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape. <b>2019</b> ,	
639	Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies. <b>2019</b> , 25, 442-448	2
638	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. <b>2019</b> , 11, 10463-10476	35
637	Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. <b>2019</b> , 9, 98	4
636	Relevance of Minimal Residual Disease in the Era of Targeted Agents. <b>2019</b> , 25, 410-417	4
635	Comparative Safety and Pharmacokinetic Evaluation of Three Oral Selenium Compounds in Cancer Patients. <b>2019</b> , 189, 395-404	6
634	Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey. <b>2019</b> , 60, 742-747	2
633	Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. <b>2019</b> , 35, 260-264	3
632	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. <b>2019</b> , 54, 1133-1137	
631	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. <b>2019</b> , 6, e38-e47	70
630	Expression and Effects of Ligand-activated Estrogen Receptors in Chronic Lymphocytic Leukemia. <b>2019</b> , 39, 167-172	2
629	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. <b>2019</b> , 33, 1161-1172	26
628	Risk of Herpes Zoster Prior to and Following Cancer Diagnosis and Treatment: A Population-Based Prospective Cohort Study. <b>2019</b> , 220, 3-11	16



627	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <b>2019</b> , 185, 961-966		6
626	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. <b>2019</b> , 144, 2695-2706		12
625	SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. <b>2019</b> , 184, 605-615		10
624	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , <b>2019</b> , 133, 494-497	2.2	18
623	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. <b>2019</b> , 104, 797-804		18
622	Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications. <b>2019</b> , 106, 44-51		13
621	Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients. <b>2019</b> , 66, 128-139		
620	Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. <b>2019</b> , 60, 1632-1643		3
619	Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis. <b>2019</b> , 185, 65-78		3
618	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <b>2019</b> , 6, e67-e78		95
617	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. <b>2019</b> , 60, 1972-1977		19
616	The E $\mu$ TCL1 Mouse Model of Chronic Lymphocytic Leukemia. <b>2019</b> , 1-29		
615	The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia. <b>2019</b> , 58, 43-51		5
614	Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods. <b>2019</b> , 1881, 211-238		3
613	CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. <b>2019</b> , 23, 340-348		16
612	Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2019</b> , 33, 969-980		70
611	CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. <b>2019</b> , 96, 143-148		19
610	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <b>2019</b> , 60, 1312-1315		1

609	Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort. <b>2019</b> , 98, 437-443		4
608	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 1011-1019	2.2	120
607	Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. <b>2019</b> , 33, 662-670		19
606	Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. <b>2019</b> , 104, e208-e210		32
605	The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells. <b>2019</b> , 25, 647-652		3
604	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <b>2019</b> , 20, 43-56		315
603	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <b>2019</b> , 104, 360-369		24
602	A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. <b>2019</b> , 60, 845-847		6
601	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <b>2019</b> , 60, 1000-1005		11
600	Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. <b>2019</b> , 110, 77-87		15
599	Wearable and flexible electronics for continuous molecular monitoring. <b>2019</b> , 48, 1465-1491		551
598	Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. <b>2020</b> , 26, 743-752		1
597	Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. <b>2020</b> , 11, 19-23		2
596	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <b>2020</b> , 34, 787-798		185
595	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. <b>2020</b> , 51, 259-264		
594	Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. <b>2020</b> , 34, 924-928		1
593	Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?. <b>2020</b> , 36, 84-90		
592	Mature lymphoid neoplasms. <b>2020</b> , 603-625		

591	HIF-1 $\beta$ is over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <b>2020</b> , 105, 1042-1054	23
590	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <b>2020</b> , 55, 172-181	8
589	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <b>2020</b> , 34, 441-450	4
588	Atlas of Cytopathology and Radiology. <b>2020</b> ,	
587	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. <b>2020</b> , 20, 174-183.e3	11
586	Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. <b>2020</b> , 574, 118895	7
585	98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. <b>2020</b> , 9, 999-1007	2
584	Significance of NOTCH1 mutations dElections in T-acute lymphoblastic leukemia patients. <b>2020</b> , 27, 157-162	6
583	A First-in-human Study of Tenalisib (RP6530), a Dual PI3K $\alpha/\beta$ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <b>2020</b> , 20, 78-86	9
582	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. <b>2020</b> , 13, 39-53	5
581	Chronic Lymphocytic Leukemia. <b>2020</b> , 1850-1871.e5	1
580	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <b>2020</b> , 38, 3805-3815	48
579	Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. <b>2020</b> , 8, e00649	1
578	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <b>2020</b> , 38, 4042-4054	66
577	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <b>2020</b> , 4, 5093-5106	0
576	Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. <b>2020</b> , 10, 16357	2
575	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. <b>2020</b> , 4, 4802-4811	12
574	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <b>2020</b> , 97, 106432	16

573	The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. <b>2020</b> , 116, 104524	2
572	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <b>2020</b> , 26, 1569-1575	109
571	Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. <b>2020</b> , 61, 2738-2742	2
570	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <b>2020</b> , 40, 4059-4066	3
569	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <b>2020</b> , 65, 371-377	2
568	ARDS as the Presenting Complication of Hyperviscosity Syndrome in Chronic Lymphocytic Leukemia: A Case Report. <b>2020</b> , 27, 48-50	
567	Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay. <b>2020</b> , 10, 597730	0
566	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2020</b> , 61, 3188-3197	9
565	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <b>2020</b> , 83, 1581-1589	2
564	Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. <b>2020</b> , 42, 261-268	4
563	HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. <b>2020</b> , 39, 5756-5767	3
562	High CXCR3 on Leukemic Cells Distinguishes from in Chronic Lymphocytic Leukemia: Evidence from CD5 and CD5 Clones. <b>2020</b> , 2020, 7084268	1
561	Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study. <b>2020</b> , 17,	0
560	Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. <b>2020</b> , 147, 2780-2792	6
559	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. <b>2020</b> , 7, CD012022	10
558	Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. <b>2021</b> , 106, 2334-2344	7
557	Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation. <b>2020</b> , 31, 1879-1891	11
556	Relation of Neutrophil Gelatinase-Associated Lipocalin Overexpression to the Resistance to Apoptosis of Tumor B Cells in Chronic Lymphocytic Leukemia. <b>2020</b> , 12,	2

555	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <b>2020</b> , 190, 901-908	8
554	Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. <b>2020</b> , 191, 426-432	1
553	Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. <b>2020</b> , 4, 3669-3676	0
552	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <b>2020</b> , 38, 3626-3637	34
551	Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients. <b>2020</b> , 2020, 6545921	7
550	Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. <b>2020</b> , 13, 412	1
549	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <b>2020</b> , 1, 537-544	0
548	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <b>2020</b> , 9, 8468-8479	8
547	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. <b>2020</b> , 10, 1-5	1
546	High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. <b>2020</b> , 12,	3
545	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <b>2020</b> , 99, 2343-2349	2
544	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. <b>2020</b> , 10, 86	5
543	Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. <b>2020</b> , 50, 1395-1402	2
542	Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia. <b>2020</b> , 29, 777-785	
541	Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia. <b>2020</b> , 12, 9977-9985	2
540	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <b>2020</b> , 26, 2810-2818	32
539	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. <b>2020</b> , 13, 48	41
538	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , <b>2020</b> , 135, 2182-2191	2.2 31

537	Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. <b>2020</b> , 38, 509-516	2
536	Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. <b>2020</b> , 34, 2934-2950	5
535	Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation. <b>2020</b> , 38, 1796-1806	0
534	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , <b>2020</b> , 135, 1859-1869	2.2 45
533	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <b>2020</b> , 38, 2849-2861	13 <sup>1</sup>
532	Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. <b>2021</b> , 106, 1867-1875	3
531	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. <i>Blood</i> , <b>2020</b> , 136, 1632-1644	2.2 50
530	Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. <b>2020</b> , 18, 2672-2684	10
529	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <b>2020</b> , 10, 848	2
528	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <b>2020</b> , 61, 1653-1659	2
527	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. <b>2020</b> , 10, 394-405	38
526	Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia. <b>2020</b> , 99, 1081-1091	
525	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <b>2020</b> , 26, 2096-2103	18
524	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2020</b> , 16, 517-523	23
523	Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. <b>2020</b> , 36, 1481-1495	2
522	Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. <b>2020</b> , 9, 14	36
521	Chronic Lymphocytic Leukemia: Real-World Data From India. <b>2020</b> , 6, 866-872	7
520	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <b>2020</b> , 12,	2

519	Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. <b>2020</b> , 34, 1760-1774	20
518	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. <b>2020</b> , 9,	7
517	Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. <b>2020</b> , 105, 2868-2871	0
516	Biosimilar monoclonal antibodies for cancer treatment. <b>2020</b> ,	0
515	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <b>2020</b> , 34, 2038-2050	19
514	Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). <b>2020</b> , 4, e336	15
513	Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience. <b>2020</b> , 61, 1645-1652	8
512	Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20'468 patients diagnosed in the Netherlands between 1989 and 2016. <b>2020</b> , 189, 574-577	5
511	Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12. <b>2020</b> , 22, 571-578	4
510	Smartphone based on-chip fluorescence imaging and capillary flow velocity measurement for detecting ROR1+ cancer cells from buffy coat blood samples on dual-layer paper microfluidic chip. <b>2020</b> , 153, 112042	17
509	RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome. <b>2020</b> , 10, 6	8
508	A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia. <b>2020</b> , 15, e0226879	0
507	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. <b>2020</b> , 11, 577	32
506	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <b>2020</b> , 105, 2671-2674	
505	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , <b>2020</b> , 135, 1204-1213	2.2 81
504	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <b>2020</b> , 95, 906-917	6
503	Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples. <b>2020</b> , 98, 529-535	4
502	Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. <b>2020</b> , 8,	7



501	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. <b>2020</b> , 11, 762		31
500	Specific Features of Interactions between Megakaryocytic and Granulocytic Hematopoiesis Lineages and Myelofibrosis during the Acute Phase of Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. <b>2020</b> , 168, 734-738		
499	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <b>2020</b> , 26, 3546-3556		4
498	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <b>2020</b> , 4, 1407-1418		3
497	How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. <b>2020</b> , 42, 103-110		26
496	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. <b>2020</b> , 395, 1278-1291		201
495	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <b>2020</b> , 38, 2862-2871		45
494	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. <b>2020</b> , 26, 3918-3927		69
493	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <b>2020</b> , 4, 165-173		17
492	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <b>2020</b> , 20, 548-555.e4		5
491	Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. <b>2021</b> , 106, 692-700		1
490	Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia. <b>2021</b> , 23, 92-99		1
489	Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles. <b>2021</b> , 48, 72-76		1
488	Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 39, 267-269		1
487	Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia. <b>2021</b> , 35, 2025-2033		4
486	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , <b>2021</b> , 137, 1019-1023	2.2	1
485	Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. <b>2021</b> , 27, 53.e1-53.e8		1
484	Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2021</b> , 137, 1117-1120	2.2	13



483	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies. <b>2021</b> , 29, 636-644	26
482	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. <b>2021</b> , 35, 1610-1620	4
481	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2021</b> , 32, 23-33	92
480	Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. <i>Blood</i> , <b>2021</b> , 137, 2182-2195	2.2 2
479	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. <b>2021</b> , 106, 320-326	1
478	Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. <b>2021</b> , 62, 791-800	0
477	A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia. <b>2021</b> , 51, 408-415	1
476	Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features. <b>2021</b> , 43, 515-525	3
475	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <b>2021</b> , 2, 54-69	6
474	Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel. <b>2021</b> , 62, 1136-1145	3
473	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. <b>2021</b> , 62, 1129-1135	5
472	Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. <b>2021</b> , 113, 370-380	3
471	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <b>2021</b> , 35, 1064-1072	12
470	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. <b>2021</b> , 46, 100758	4
469	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <b>2021</b> , 35, 1597-1609	3
468	Leukemia: Trends in treatment and how close we have achieved eradication. <b>2021</b> , 547-587	
467	Diagnostic Value of Plasma miR-145 and miR-185 as Targeting of the APRIL Oncogene in the B-cell Chronic Lymphocytic Leukemia. <b>2021</b> , 22, 111-117	4
466	Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks. <b>2021</b> , 11, 322	0

465	Chronic lymphocytic leukemia prognostic models in real life: still a long way off. <b>2021</b> , 14, 137-141	5
464	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <b>2021</b> , 12, 665	3
463	Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. <b>2021</b> , 90, 107226	4
462	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. <b>2021</b> , 27, 2190-2199	33
461	Effect of IL-27 on activity of bone marrow NK cells of patient with B-chronic lymphocytic leukemia in vitro. <b>2021</b> , 23, 131-138	
460	Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia. <b>2021</b> , 12, 20-28	
459	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia. <b>2021</b> , 51, 348-354	
458	Myeloid neoplasms in the setting of chronic lymphocytic leukaemia/chronic lymphocytic leukaemia-like disease: a clinicopathological study of 66 cases comparing cases with prior history of treatment to those without. <b>2021</b> ,	
457	Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. <b>2021</b> , 193, 769-778	4
456	Unexpected hematologic malignancies after prostatectomy: Case report and literature review. <b>2021</b> , 88, 382-385	1
455	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. <b>2021</b> , 13, 1459-1476	0
454	Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. <b>2021</b> , 27, 80-96	1
453	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <b>2021</b> , 39, 1099-1105	2
452	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <b>2021</b> , 106, 2364-2373	21
451	Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. <b>2021</b> , 11, 5127	1
450	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. <b>2021</b> , 62, 1816-1827	
449	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. <b>2021</b> , 34, 108845	
448	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <b>2021</b> , 2, 266-271	3

- 447 Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. **2021**, 39, 326-335 3
- 446 Clinicopathological features of Chinese patients with B-cell lymphoproliferative disorders and kidney infiltration. **2021**, 26, 650-658
- 445 Safety of switching between rituximab biosimilars in onco-hematology. **2021**, 11, 5956 2
- 444 References. **2021**, 301-427
- 443 Optimizing Treatment of Chronic Lymphocytic Leukemia. **2021**, 12, 325-328
- 442 Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies. **2021**, 27, 1609742 2
- 441 Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada. **2021**, 103, 106538
- 440 Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol. **2021**, 106, 831-835 3
- 439 Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. **2021**, 62, 2392-2399 0
- 438 Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review. **2021**, 12, 225-234 1
- 437 Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. **2021**, 8, e254-e266 9
- 436 3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. **2021**, 12, 639572 3
- 435 COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. **2021**, 194, 646-650 1
- 434 The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. **2021**, 11, 2
- 433 Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options. *Blood*, **2021**, 2.2 5
- 432 A rare cause of postmenopausal bleeding: chronic lymphocytic leukemia. **2021**, 1-3
- 431 Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. **2021**, 35, 3421-3429 5
- 430 Clinical outcome and prognostic factors in dogs with B-cell chronic lymphocytic leukemia: A retrospective study. **2021**, 35, 1918-1928 2

429	Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. <b>2021</b> , 112, 2405-2415		1
428	Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies. <b>2021</b> , 21, e432-e448		6
427	Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients. <b>2021</b> , 13,		0
426	Monoclonal B lymphocytosis in a kidney transplant recipient. <b>2021</b> , 14,		
425	O-GlcNAcylation in early stages of chronic lymphocytic leukemia: Protocol development for flow cytometry. <b>2021</b> , 32, 353-362		
424	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. <b>2021</b> ,		8
423	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , <b>2021</b> , 138, 836-846	2.2	6
422	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , <b>2021</b> , 137, 3507-3517	2.2	12
421	3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells. <b>2021</b> , 9, 655773		0
420	-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than mutation load. <b>2021</b> ,		1
419	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. <b>2021</b> , 10, 4387-4396		2
418	Acalabrutinib in treatment-naïve chronic lymphocytic leukemia. <i>Blood</i> , <b>2021</b> , 137, 3327-3338	2.2	18
417	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <b>2021</b> , 39, 3441-3452		65
416	Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia. <b>2021</b> ,		0
415	The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center. <b>2021</b> , 16, 59		1
414	BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. <b>2021</b> , 12, 686768		4
413	Il percorso diagnostico terapeutico assistenziale per la gestione delle sindromi linfoproliferative croniche nell'Ulss7 della regione Veneto: a che punto siamo?.		
412	Impact of Berberine on the Expression of Apollon Gene in Chronic Lymphocytic Leukemia. <b>2021</b> , 1,		

4 <sup>11</sup>	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <b>2021</b> ,		1
4 <sup>10</sup>	Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. <b>2021</b> , 9,		3
4 <sup>09</sup>	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. <b>2021</b> , 7, 1213-1219		17
4 <sup>08</sup>	Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. <b>2021</b> , 6,		1
4 <sup>07</sup>	Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib. <i>Blood</i> , <b>2021</b> ,	2.2	1
4 <sup>06</sup>	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <b>2021</b> , 11, 684621		1
4 <sup>05</sup>	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. <b>2021</b> , 1-12		1
4 <sup>04</sup>	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. <b>2021</b> , 51, 100884		
4 <sup>03</sup>	Chronic Lymphocytic Leukemia in a Cockatiel (). <b>2021</b> , 35, 341-349		
4 <sup>02</sup>	Management of autoimmune complications in patients with lymphoid cancer. <i>Blood</i> , <b>2021</b> ,	2.2	0
4 <sup>01</sup>	Towards a Better Characterisation of Leukemic Cells in Chronic Lymphocytic Leukaemia: Cell-Size Heterogeneity Reflects Their Activation Status and Migratory Abilities. <b>2021</b> , 13,		0
4 <sup>00</sup>	Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. <b>2021</b> ,		
399	A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. <b>2021</b> , 39, 595-604		3
398	Chronic lymphocytic leukemia in a young population. <b>2021</b> , 110, 106668		0
397	LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia. <b>2021</b> , 110, 106706		2
396	Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax. <b>2021</b> , 2021, 8831125		1
395	Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. <b>2021</b> , 36, 194-204		3
394	Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. <b>2021</b> , 106, 2022-2025		4

393	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <b>2021</b> , 100, 825-830	1
392	Chronic Lymphocytic Leukemia. 211-227	1
391	Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases. <b>2017</b> , 92, E171-E173	5
390	Acquired genomic copy number aberrations in CLL. <b>2013</b> , 792, 47-86	4
389	TP53 aberrations in chronic lymphocytic leukemia. <b>2013</b> , 792, 109-31	14
388	Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. <b>2014</b> , 1109, 209-37	3
387	B Lymphocytes in Cancer Immunology. <b>2011</b> , 37-57	5
386	Cytogenetic methods in chronic lymphocytic leukemia. <b>2011</b> , 730, 119-30	15
385	Algorithm for Constructing a Classifier Team Using a Modified PCA (Principal Component Analysis) in the Task of Diagnosis of Acute Lymphocytic Leukaemia Type B-CLL. <b>2019</b> , 614-624	2
384	Cytopathology in the diagnosis of lymphoma. <b>2014</b> , 160, 211-40	5
383	Mature B-Cell Neoplasms. <b>2011</b> , 221-246	4
382	World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001]. <b>2011</b> , 57, 66-73	5
381	Chronic lymphocytic leukemia/small lymphocytic lymphoma. 81-102	1
380	Novel genes exhibiting DNA methylation alterations in Korean patients with chronic lymphocytic leukaemia: a methyl-CpG-binding domain sequencing study. <b>2020</b> , 10, 1085	1
379	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia.	2
378	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. <b>2021</b> , 193, 133-137	2
377	Relevance of TP53 for CLL diagnostics. <b>2019</b> , 72, 343-346	6
376	LC-FACSeq is a method for detecting rare clones in leukemia. <b>2020</b> , 5,	1

- 375 CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. **2018**, 128, 5465-5478 24
- 374 A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?. **2012**, 2012, 97-104 11
- 373 In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. *Blood*, **2017**, 129, 3495-3498 2.2 53
- 372 Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. *Blood*, **2020**, 135, 510-513 2.2 6
- 371 Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. *Blood*, **2020**, 136, 93-105 2.2 34
- 370 Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. **2017**, 18, 516-519 3
- 369 Clinical and Laboratory Features of CD5-Negative Chronic Lymphocytic Leukemia. **2017**, 23, 2137-2142 11
- 368 Advances in treating chronic lymphocytic leukemia. **2014**, 6, 65 12
- 367 Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. **2012**, 7, e52808 25
- 366 A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells. **2013**, 8, e67601 10
- 365 Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. **2013**, 8, e75252 19
- 364 Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. **2015**, 10, e0118801 12
- 363 Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. **2015**, 10, e0129544 21
- 362 Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia. **2015**, 10, e0137232 19
- 361 HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. **2017**, 12, e0172978 2
- 360 Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. **2017**, 12, e0179841 5
- 359 Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. **2017**, 12, e0179883 7
- 358 How I treat elderly or comorbid patients with chronic lymphocytic leukemia. **2010**, 53, 213-20 3



357	Biological prognostic markers in chronic lymphocytic leukemia. <b>2009</b> , 52, 3-8	9
356	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. <b>2019</b> , 8, 1-10	5
355	Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects. <b>2016</b> , 9, e5069	9
354	Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia. <b>2020</b> , 12, 16083-16098	3
353	Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. <b>2016</b> , 7, 46301-46314	14
352	Telomere status in chronic lymphocytic leukemia with TP53 disruption. <b>2016</b> , 7, 56976-56985	14
351	Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia. <b>2016</b> , 7, 60986-60999	10
350	A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. <b>2017</b> , 8, 22104-22112	5
349	NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. <b>2016</b> , 7, 68513-68526	32
348	Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. <b>2016</b> , 7, 82400-82410	19
347	A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. <b>2016</b> , 7, 78269-78280	7
346	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <b>2017</b> , 8, 3274-3288	10
345	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. <b>2014</b> , 5, 140-9	9
344	Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. <b>2017</b> , 8, 11219-11227	17
343	Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. <b>2017</b> , 8, 12953-12967	26
342	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <b>2017</b> , 8, 25455-25468	7
341	CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. <b>2017</b> , 8, 42571-42587	31
340	Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. <b>2017</b> , 8, 84889-84901	18



339	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. <b>2017</b> , 8, 79864-79875	10
338	Gene-body hypermethylation controlled cryptic promoter and miR26A1-dependent EZH2 regulation of TET1 gene activity in chronic lymphocytic leukemia. <b>2017</b> , 8, 77595-77608	4
337	Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. <b>2015</b> , 6, 2667-79	35
336	Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. <b>2018</b> , 9, 3353-3364	3
335	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. <b>2018</b> , 9, 19136-19146	5
334	A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. <b>2018</b> , 9, 26019-26031	5
333	Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. <b>2018</b> , 9, 31590-31605	15
332	Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study. <b>2018</b> , 9, 29944-29956	5
331	miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. <b>2015</b> , 6, 1276-85	32
330	Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <b>2019</b> , 10, 3827-3830	2
329	Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. <b>2015</b> , 6, 5426-34	40
328	CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF- $\kappa$ B mediated pathway. <b>2015</b> , 6, 15931-9	7
327	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <b>2015</b> , 6, 19102-17	13
326	Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. <b>2015</b> , 6, 16559-72	28
325	Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. <b>2015</b> , 6, 18653-63	16
324	Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. <b>2015</b> , 6, 32061-74	9
323	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. <b>2015</b> , 6, 44422-36	16
322	Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia. <b>2016</b> , 7, 2135-42	12

321	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. <b>2016</b> , 7, 4598-610	34
320	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <b>2016</b> , 7, 20520-31	24
319	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. <b>2016</b> , 7, 32846-53	32
318	The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. <b>2016</b> , 7, 35946-35959	27
317	The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. <b>2016</b> , 7, 45429-45443	10
316	Role of Defects of Hematopoietic and Lymphoid Niches in Genesis of Chronic Lymphocytic Leukemia. <b>2016</b> , 9, 176-190	1
315	Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. <b>2017</b> , 10, 271-281	1
314	Immunological Synapse in the Biology of Chronic Lymphocytic Leukemia. <b>2018</b> , 11, 313-318	2
313	Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis. <b>2020</b> , 27, 282-297	14
312	Ofatumumab for the treatment of chronic lymphocytic leukemia. <b>2009</b> , 6, 577-587	1
311	Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia Patients. <b>2017</b> , 2, 025-033	1
310	TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population. <b>2019</b> , 20, 1579-1585	2
309	The Treatment of Chronic Lymphatic Leukemia. <b>2019</b> , 116, 41-46	7
308	The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. <b>2010</b> , 14, 27-32	6
307	Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy in Chronic lymphocytic leukaemia (ARCTIC) trial. <b>2017</b> , 21, 1-17	11
306	THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT. <b>2018</b> , 23, 283-301	2
305	[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2018 edition)]. <b>2018</b> , 39, 353-358	2
304	Chronic lymphocytic leukemia: a clinical review including Korean cohorts. <b>2016</b> , 31, 433-43	6

303	Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis. <b>2012</b> , 132, 2056-9	7
302	Familial occurrence of chronic lymphocytic leukaemia in Norway. <b>2012</b> , 132, 2060-3	4
301	The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology. <b>2010</b> , 7, 20	8
300	Overview of recent developments in chronic lymphocytic leukemia. <b>2012</b> , 1, 84-9	1
299	Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program. <b>2017</b> , 38, 508-515	4
298	Anticipation in families with chronic lymphocytic leukemia and other lymphoproliferative disorders. <b>2010</b> , 4, 1-9	4
297	EBV-miR-BHRF1-1 Targets p53 Gene: Potential Role in Epstein-Barr Virus Associated Chronic Lymphocytic Leukemia. <b>2020</b> , 52, 492-504	4
296	Comprehensive Genetic Analysis by Integration of Conventional Karyotyping and Interphase FISH Helps Refinement of Biological Subclasses with Clinical Impact in Chronic Lymphocytic Leukemia. <b>2016</b> , 07, 427-438	1
295	Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia. <b>2018</b> , 09, 576-587	1
294	Evaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia. <b>2016</b> , 33, 335-338	1
293	Advanced chronic lymphoid leukemia with severe bronchopneumonia: an Autopsy Case Report. <b>2016</b> , 6, 11-20	1
292	The current lymphoma classification: new concepts and practical applications triumphs and woes. <b>2012</b> , 32, 296-305	5
291	Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature. <b>2016</b> , 36, 364-366	2
290	Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease. <b>2015</b> , 16, 6007-10	5
289	Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy. <b>2015</b> , 16, 8533-9	1
288	Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it?. <b>2016</b> , 17, 215-7	2
287	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <b>2014</b> , 3,	37
286	Application of an Artificial Neural Network in the Diagnosis of Chronic Lymphocytic Leukemia. <b>2019</b> , 11, e4004	6

- 285 Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia. **2013**, 7, 1366-71 4
- 284 A case of chronic lymphocytic leukemia with unmutated variable region of the immunoglobulin heavy chain gene with markedly high lactate dehydrogenase responding to ibrutinib. **2021**, 12, 172
- 283 Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. **2021**, 181, 133-149
- 282 Organic Bioelectronic Devices for Metabolite Sensing. **2021**, 9
- 281 Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. **2021**, 1-11 1
- 280 Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia. **2021**, 1-8 0
- 279 Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal-Results from a population-based cancer registry cohort study. **2021**, 16, e0258423 1
- 278 Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis. **2021**, 111, 106729
- 277 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. **2021**, 39, 3853-3865 17
- 276 The cure of leukemia through the optimist's prism. **2021**, 128, 240 2
- 275 Differential Levels of mRNAs in Normal B Lymphocytes, Monoclonal B Lymphocytosis and Chronic Lymphocytic Leukemia Cells from the Same Family Identify Susceptibility Genes. **2021**, 9, 621-634 0
- 274 Processing human lymph node samples for single-cell assays. **2021**, 2, 100914 0
- 273 New Therapies in Chronic Lymphocytic Leukemia. **2008**, 165-184 1
- 272 Etiology of CLL. **2008**, 69-89
- 271 Frontline Therapy of Chronic Lymphocytic Leukemia. **2008**, 121-139
- 270 Molecular Basis of Lymphoid and Myeloid Diseases. **2009**, 265-290
- 269 Case 26. **2009**, 166-171
- 268 A Case of CD5 Negative Chronic Lymphocytic Leukemia. **2009**, 44, 255

267 Case 28. **2009**, 178-183

266 Pretreated Chronic Lymphocytic Leukemia: Use of Alemtuzumab. **2010**, 343-358

265 Differenzialdiagnostik und Differenzialtherapie - Pages 483-493. **2010**, 483-493

o

264 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2010**, 211-220

263 Chronic lymphoid leukemias and heavy chain disease. **2010**, 484-496

262 Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia. **2010**, 14, 19-26

1

261 Overview of the Lymphoid Neoplasms. **2012**, 3-39

260 Bone marrow. **2011**, 1927-2012

259 Therapy of Chronic Lymphocytic Leukemia: Front-Line and Salvage. 308-314

258 Lymphomas of the Bone Marrow. **2011**, 341-393

257 Chronic Lymphocytic Leukemia: Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers. 297-307

256 Hämatologische und onkologische Erkrankungen. **2011**, 607-718

255 Lymphoid Leukaemias of Mature T, B and Natural Killer Cells. 301-376

254 Diseases. 160-300

253 Chronic Lymphocytic Leukemia (CLL). **2012**, 67-96

252 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.

251 B-Cell Leukemias of Mature Lymphocytes. **2012**, 387-402

250 Cutaneous lymphoproliferative diseases and related disorders. **2012**, 1311-1420

249 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

248 Small B-Cell Lymphomas. **2012**, 205-260

247 Bone Marrow Involvement in Primary Mature B and T Cell Leukemias. **2012**, 171-189

246 5 Kwaadaardige aandoeningen van het immuunsysteem. **2012**, 63-70

245 To treat or not to treat. **2012**, 26-34

244 Transplant in chronic lymphocytic leukemia: to do it or not and if so, when and how?. **2012**, 399-404

243 Chronic Lymphocytic Leukemia-Era of Targeted Therapy. **2013**, 85, 141

2

242 Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. **2013**, 65-82

241 The World Health Organization Classification of Lymphoid Neoplasms. **2013**, 1-34

240 Chronic Lymphocytic Leukaemia.

239 MicroRNAs in Hematologic Malignancies. **2014**, 67-95

238 Chronische lymphatische Leukämie. **2014**, 1-10

237 MicroRNAs and Chronic Lymphocytic Leukemia. **2014**, 159-178

236 Molecular Testing in Hematologic Malignancies. **2014**, 135-167

235 Chronic Lymphocytic Leukemia. **2014**, 1958-1978.e7

234 The Diagnostic Value of Flow Cytometry Immunophenotyping in an Albanian Patient Population with a Preliminary Clinical Diagnosis of Chronic Lymphocytic Leukemia. **2014**, 2, 51-55

233 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.

232 Chronic Lymphocytic Leukemia (CLL). **2015**, 113-128

231 Lenalidomide following fludarabine and rituximab in previously untreated CLL. **2015**, 3, 2

230 Maligne Lymphome. **2015**, 1-11

229 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

228 ZAP-70 protein expression in B-cell chronic lymphoid leukemia: a single center experience from Pakistan. **2015**, 16, 1587-90

4

227 Chronic lymphocytic leukemia/small lymphocytic lymphoma. 133-144

226 Mature B- and T-cell neoplasms and Hodgkin lymphoma. 252-331

1

225 The Role of Tumor Necrosis Factor and ITS Soluble Receptors in Myelosuppression Developing in B-Cell Chronic Lymphocytic Leukemia. **2015**, 2-3, 36-41

224 Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia. **2016**, 9, 162-175

0

223 HIV and Indolent Lymphoma. **2016**, 107-117

222 Chronic Lymphocytic Leukemia: Prognostic Significance of Minimal Residual Disease and Potential of Modern Methods of Its Diagnosis and Therapy (Literature Review). **2016**, 9, 191-198

221 Diagnostic Applications of Nuclear Medicine: Leukemias. **2016**, 1-31

220 Cytogenetics: Applications. **2016**, 67-82

219 A case of Hodgkin's lymphoma arising in the maxillary gingiva. **2016**, 62, 561-565

218 Increasing the Efficacy of Detecting Residual Cancer Cells Using a Whole-Slide Image Scanning Method and a Computer-Aided Detection Scheme. **2016**, 1,

217 Prevalence of cytogenetic abnormalities in chronic lymphocytic leukemia in the southern part of Turkey. **2017**, 54, 572-575

0

216 Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia. **2017**, 47-73

215 Indolente (niedrig maligne) Non-Hodgkin-Lymphome. **2017**, 437-484

214 Chronische lymphatische Leukämie beim alten und geriatrischen Patienten. **2017**, 1-12

213 Diagnostic Applications of Nuclear Medicine: Leukemias. **2017**, 435-465

212 Chronic Lymphocytic Leukemia (CLL): Upfront Treatment Options in 2017. **2017**, 4,

211 TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases. **2017**, 34, 34-39

210 Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience. **2017**, 1, 26-31

209 Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. **2017**, 11, 108-114

208 [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study]. **2017**, 89, 57-64 2

207 An unusual presentation of chronic lymphocytic leukemia. **2017**, 7, 133-136 5

206 Chronic Lymphocytic Leukemia in Older Adults. **2018**, 1-13

205 Watch and Wait Actualities in the Treatment of Chronic Lymphocytic Leukemia. **2017**, 2, 25-30

204 B-Cell Leukemias of Mature Lymphocytes. **2018**, 397-413.e2

203 Literaturverzeichnis. **2018**, 503-517

202 Chronische lymphatische Leukämie beim alten und geriatrischen Patienten. **2018**, 249-260

201 Small Lymphocytic Lymphoma. **2018**, 344-345

200 Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. **2018**, 11, 167-174

199 Autoimune haemolytic anaemia as a complication of a Chronic Lymphocytic Leukaemia. **2018**, 20, e9-e14

198 Indolente und kleinzellige B-Zell Lymphome. **2019**, 523-600

197 A Rare Instance of Simultaneous Infection with Disseminated Nocardia and Pulmonary Aspergillus in a Patient Receiving Treatment with Ibrutinib for Chronic Lymphocytic Leukemia. **2018**, 10, e3427

196 Expression of the apoptosis-related genes in patients with newly diagnosed chronic lymphocytic leukemia in clinical data context. **2018**, 17, 41-46 1



195 Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. **2019**, 401-409

194 Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR). **2018**, 46, 734-741

193 KRONİK LENFOSİTİK LEMFEMDE TANI ANINDA HİPOGAMMAGLOBULİNEMİSİ KALIM VE ENFEKSİYON RİSKİNERİNDE ETKİLERİ.

192 Hybrid Imaging and Radionuclide Therapy in Hemato-oncology. **2019**, 655-705

191 The EBTCL1 Mouse Model of Chronic Lymphocytic Leukemia. **2019**, 2213-2241

190 Results of chemotherapy in the treatment of chronic lymphoid leukemia in Black Africa: Experience of Cote d'Ivoire. **2019**, 3, 045-048

189 Chronic lymphocytic leukemia with deletion 17p: An Indian scenario. **2019**, 8, 40

0

188 Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. **2019**, 107-119

1

187 Development of methods to evaluate probability of reviewer assessment bias in blinded independent central review (BICR) imaging studies. **2019**,

186 Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia [preliminary results]. **2019**, 50, 15-20

185 Autoimmune cytopenias in chronic lymphocytic leukemia. **2019**, 35, 1334-1338

184 Hematopathology. **2020**, 59-67

183 Maintenance therapy for chronic lymphocytic leukaemia.

78

182 Lymph Nodes and Spleen. **2020**, 65-100

181 Chronic lymphocytic leukaemia. **2020**, 5302-5310

180 IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia. **2021**, 8, 24-30

0

179 Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients. **2020**, 21, 1295-1301

1

178 Co-Existence of Chronic Lymphocytic Leukaemia and Malignancy of Uterine Cervix. **2020**, 9, 1522-1524

1

177	Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects. <b>2020</b> , 12, e8908	2
176	Morphological and immunofenotypic features of the monoclonal population of B-lymphocytes in chronic lymphocytic leukemia. <b>2020</b> , 1, 27-35	1
175	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. <b>2021</b> , JCO2101181	10
174	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. <b>2021</b> ,	0
173	Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. <b>2021</b> ,	
172	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <b>2021</b> ,	6
171	Recent Progress in Intelligent Wearable Sensors for Health Monitoring and Wound Healing Based on Biofluids. <b>2021</b> , 9, 765987	3
170	Chronic Lymphocytic Leukemia in Older Adults. <b>2020</b> , 521-533	
169	Pattern of Immunocompetent Peripheral Blood Cell Subpopulations in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <b>2020</b> , 13, 395-405	
168	Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. <b>2020</b> , 164, 425-434	
167	Demographic pattern of chronic lymphocytic leukemia in a tertiary hospital in Calabar, South-South Nigeria. <b>2020</b> , 19, 203-206	0
166	Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia. <b>2020</b> , 71, 47-53	
165	Small B-Cell Lymphomas With and Without Plasmacytic Differentiation. <b>2020</b> , 87-121	
164	Dielectric spectroscopy of blood serum of patients with chronic lymphocytic leukemia. <b>2020</b> ,	1
163	Lymphomes. <b>2020</b> , 241-255.e3	
162	HIGH-RISK SUBTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA ARE DETECTABLE AS EARLY AS 16 YEARS PRIOR TO DIAGNOSIS. <i>Blood</i> , <b>2021</b> ,	2.2 1
161	BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production. <b>2021</b> , 10,	1
160	[Synchronous lymphoma and carcinoma-clinical analyses of 17 patients]. <b>2018</b> , 39, 277-280	2

159	Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. <b>2010</b> , 2, 119-126	10
158	Tailoring of chronic lymphatic leukemia therapy. <b>2013</b> , 3, 201-9	
157	Monoclonal B-cell lymphocytosis. <b>2014</b> , 8, 75-9	5
156	Metadherin contribute to BCR signaling in chronic lymphocytic leukemia. <b>2014</b> , 7, 1588-94	6
155	Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. <b>2014</b> , 39, 483-519	29
154	Synchronous breast carcinoma and chronic lymphocytic leukemia in a Chinese young female: a rare combination. <b>2015</b> , 8, 5952-4	1
153	Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population. <b>2015</b> , 8, 11235-43	1
152	Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies. <b>2015</b> , 8, 157-62	11
151	Dicer Gene Expression as a Prognostic Factor in Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia in Fars Province. <b>2016</b> , 41, 223-9	3
150	Frequency of monoclonal B-cell lymphocytosis in relatives of patients with chronic lymphocytic leukemia. <b>2016</b> , 47, 81-6	
149	New Pharmacotherapies in Chronic Lymphocytic Leukemia. <b>2017</b> , 42, 106-115	1
148	Chronic Lymphocytic Leukemia and the Side Effects of Therapy: 2017 Review. <b>2017</b> , 114, 195-198	1
147	A Double-Blind, Randomized Comparison Study between Zytux <sup>®</sup> vs MabThera <sup>®</sup> in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial. <b>2018</b> , 12, 84-91	5
146	Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter. <b>2018</b> , 17, 51-56	1
145	Prognosis Factors in Chronic Lymphocytic Leukemia. <b>2012</b> , 5, 48-53	
144	Chronic lymphocytic leukemia followed by myelodysplastic syndrome and erythroleukemia. <b>2012</b> , 5, 6-11	
143	Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia. <b>2019</b> , 11, 270-276	5
142	Association of CD49d expression with clinicopathological features of chronic lymphocytic leukemia patients in the Iranian population. <b>2020</b> , 12, 32-39	0

- 141 [How we diagnose and treat chronic lymphocytic leukemia]. **2018**, 39, 529-532 0
- 140 [Clinical analysis of 70 chronic lymphocytic leukemia patients with trisomy 12 detected by FISH]. **2018**, 39, 387-391
- 139 [The consensus for differential diagnosis of B cell chronic lymphoproliferative diseases in China (2018 edition)]. **2018**, 39, 359-365 0
- 138 [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia]. **2018**, 39, 392-397 2
- 137 [Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) patients with the aberration of p53 gene]. **2016**, 37, 308-12 0
- 136 [Prognostic value of activated partial thromboplastin time and D-dimer in chronic lymphocytic leukemia]. **2021**, 42, 425-427
- 135 [Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia]. **2021**, 42, 543-548
- 134 Graphene-enabled wearable sensors for healthcare monitoring. **2022**, 197, 113777 14
- 133 Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype.. **2021**, 11, 788761 3
- 132 The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. *Blood*, **2021**, 2.2 5
- 131 Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. **2021**, 62, 3160-3169
- 130 Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome. *Blood*, **2021**, 2.2 8
- 129 Elastin Microfibril Interfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia. **2021**, 0
- 128 Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. **2021**, 5, e664
- 127 Second Primary Malignancies in Chronic Lymphocytic Leukaemia; Skin, Solid Organ, Haematological, and Richter's Syndrome.
- 126 The fragility index in 2010-2021 chronic lymphocytic leukemia randomized controlled trials. **2021**,
- 125 Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability.. **2021**, 11, 771664 0
- 124 The significance of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq. **2021**, 10, 146

123	The pattern of bone marrow involvement among chronic lymphocytic leukemia patients and its impact on the disease outcome in Kurdistan Region of Iraq. <b>2021</b> , 10, 158		
122	Prediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia. <b>2021</b> , 14, 466-476		
121	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). <b>2021</b> , 106, 2834-2844		1
120	Bone Marrow Changes Following Therapy and Immunosuppression. <b>2020</b> , 314-339		0
119	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.. <b>2022</b> , 1-12		2
118	Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations.. <b>2022</b> , 25,		0
117	Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. <b>2022</b> , 1,		4
116	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.. <b>2022</b> ,		9
115	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.. <b>2022</b> , 17, 39		
114	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.. <b>2022</b> ,		
113	Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.. <b>2022</b> , 12, 1811		0
112	Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.. <b>2022</b> , 22, 137		1
111	The Role of Cytogenetic and Molecular-Genetic Studies in Diagnostics and Prediction of the Chronic Lymphocytic Leukemia. <b>2021</b> , 78-89		
110	Personalised Prevention: Increasing or Decreasing Over-Medicalisation, Overdiagnosis and Overtreatment?. <b>2022</b> , 87-111		
109	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <i>Blood</i> , <b>2022</b> ,	2.2	10
108	Optimizing a Deep Residual Neural Network with Genetic Algorithm for Acute Lymphoblastic Leukemia Classification.. <b>2022</b> , 1		3
107	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.. <b>2021</b> ,		0
106	Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.. <b>2022</b> , 1-5		0

105	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.. <b>2022</b> ,	2
104	Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.. <b>2022</b> , 41, 64	1
103	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. <b>2022</b> , 1-9	2
102	Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.. <b>2022</b> , 1-8	0
101	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.. <b>2022</b> , 6, e707	2
100	Reduced Percentage of CD14CD16SLAN Monocytes Producing TNF and IL-12 as an Immunological Sign of CLL Progression.. <b>2022</b> , 23,	0
99	The TP63/BCL2 Axis Represents A Novel Mechanism Of Clinical Aggressiveness In Chronic Lymphocytic Leukemia.. <b>2022</b> ,	1
98	Flow Cytometry in Hematologic Neoplasia. <b>2022</b> , 515-527	
97	Guideline for the treatment of chronic lymphocytic leukaemia.. <b>2022</b> ,	0
96	Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GiVe) in patients with untreated high-risk chronic lymphocytic leukemia.. <i>Blood</i> , <b>2021</b> ,	2.2 6
95	Salivary Test Assessment in an Oncohematological Pediatric Sample: A Case Control Study. <b>2022</b> , 12, 3501	1
94	Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation.. <b>2022</b> , 12, 835290	
93	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.. <b>2022</b> , 9, e190-e199	4
92	The ClpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.	
91	Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia.. <b>2022</b> ,	4
90	Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia.. <b>2022</b> ,	8
89	A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.. <b>2022</b> ,	1
88	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. <b>2022</b> , 3, 129-138	1

- 87 Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. **2021**, 14, 1
- 86 Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.. **2021**, 5
- 85 An aggressive CD4 CD8 T-cell neoplasm in young English bulldogs. **2021**,
- 84 Outcome of chronic lymphocytic leukemia with deletion 17p. **2020**, 3, 638
- 83 Skin bioelectronics towards long-term, continuous health monitoring.. **2022**, 11
- 82 KRONİK LENFOSİTİK LEBEMİ AKALARINDA HÜCRE YÜZEY ANTİJEN EKSPRESYONLARININ DEĞERLENDİRİLMESİ **2022**, 23, 183-189
- 81 High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.. **2022**, 0
- 80 Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial.. *Blood*, **2022**, 2.2 8
- 79 Bone marrow. 813-942
- 78 Table\_1.docx. **2020**,
- 77 A Phase I trial of talazoparib in patients with advanced hematologic malignancies. **2021**, 10, IJH35
- 76 Diagnostic Applications of Nuclear Medicine: Leukemias. **2022**, 1-39
- 75 Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.
- 74 Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia.
- 73 CRISPR/Cas9 in Chronic Lymphocytic Leukemia. **2022**, 2, 928-936 1
- 72 The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.. **2022**, 1
- 71 Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. 5
- 70 Cancers of the Blood. **2022**, 67-131

- 69 CPI Adult Cancer Imaging Special Edition Module. **2019**,
- 68 Is it possible to apply individual treatments in patients with chronic lymphocytic leukemia?. **2013**, 47, 5-10
- 67 Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood*, 2.2 4
- 66 Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia.
- 65 Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients.
- 64 A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy. **2022**, 11, 3206 1
- 63 Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis. **2022**, 29, 4245-4259
- 62 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. 49
- 61 Monoclonal B-cell Lymphocytosis [a review of diagnostic criteria, biology, natural history, and clinical management. 1-12
- 60 p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF- $\kappa$ B. 12, 0
- 59 MiR-146b-5p regulates il-23 receptor complex expression in chronic lymphocytic leukemia cells. 0
- 58 Statistical handling of death events in the analysis of time to progression: A review of oncology journals. **2022**, 106858
- 57 Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial. 0
- 56 Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R.
- 55 Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. **2022**, 11
- 54 Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. 1
- 53 Detection and Characterization of Paraproteinemia in Canine Chronic B-cell Lymphocytic Leukemia Using Routine and Free Light Chain Immunofixation.
- 52 The molecular biology and therapeutic potential of Nrf2 in leukemia. **2022**, 22, 0



- 51 Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages. **2022**, 12, 1802
- 50 Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL. **2022**, 36, 2233-2241
- 49 A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
- 48 Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. 1-20
- 47 MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL. 2
- 46 Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
- 45 Effective Tumor Debulking With Ibrutinib Before Initiation of Venetoclax: Results From the CAPTIVATE Minimal Residual Disease (MRD) and Fixed-Duration (FD) Cohorts.
- 44 Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. **2022**, 122, 106945 o
- 43 Diagnostic Applications of Nuclear Medicine: Leukemias. **2022**, 529-567 o
- 42 La leucémie lymphoïde chronique, un intrus souvent discret et un objet de réflexion philosophique. **2022**, 38, 718-721 o
- 41 Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. 13, o
- 40 Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. o
- 39 CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia. **2022**, o
- 38 Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment. **2022**, 2022, 1-21 o
- 37 Custom Gold-Patterned Rewritable Optical Disc-based Plasmonic Sensor for Blood Hemoglobin Detection. o
- 36 Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model. **2022**, 10, o
- 35 Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia. o
- 34 Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. o

33	A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL.	2
32	miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study. 13,	0
31	An Exceptional Case of Light Chain Only Variant of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits Secondary to Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. <b>2022</b> , 2022, 1-7	0
30	Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. <b>2022</b> , 14, 5576	0
29	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. <b>2022</b> ,	2
28	Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. <b>2022</b> , 6, e801	3
27	Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.	2
26	Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV. 12,	0
25	Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome. <b>2022</b> , 14, 6035	0
24	NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.	0
23	Experience of using acalabrutinib therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <b>2022</b> , 86-90	0
22	Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation. <b>2023</b> , 14,	0
21	Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia. <b>2023</b> , 24, 1705	0
20	Mesenchymal stromal cell senescence in haematological malignancies.	0
19	Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for 8 Years in the RESONATE-2 Study. <b>2023</b> , 15, 507	0
18	Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <b>2023</b> , 13,	0
17	Obinutuzumab in combination with chlorambucil in first line treatment of elderly patients with chronic lymphocytic leukemia. <b>2022</b> , 67, 478-490	0
16	Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.	0

15	A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.	0
14	Tumor immunology. <b>2023</b> , 245-452	0
13	Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.	0
12	Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.	1
11	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. <b>2023</b> , 2023, 1-17	0
10	Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. <b>2023</b> , 24, 2410	0
9	Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of MYD88 Mutations. <b>2023</b> , 24, 3177	0
8	Measurable residual disease in chronic lymphocytic leukemia. 13,	0
7	Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. <b>2023</b> , 201, 353-356	0
6	Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. <b>2023</b> , 64, 712-716	0
5	The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. 13,	0
4	The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. 14,	0
3	Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. <b>2023</b> , 15, 1996	0
2	Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).	0
1	Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.	0